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ABSTRACT
Background. Maintenance of nitric oxide (NO) availability is crucial for cardiovascular 
homeostasis and protection against myocardial ischemia-reperfusion (IR) injury. The mechanisms 
underlying reduced NO availability are multifactorial and involve deficiency of the NO synthase 
(NOS) substrate L-arginine and co-factor tetrahydrobiopterin (BH4) as well as increased NO 
inactivation by reactive oxygen species. Increased activity of arginase has emerged as a key factor 
behind reduced NO availability by competing with NOS for L-arginine as substrate. The aims 
of the studies were to investigate: 1) the potential of arginase and RhoA/Rho associated kinase 
(ROCK) inhibition, supplementation of L-arginine with BH4  and remote ischemic perconditioning 
(RIPerc) to induce cardioprotection, 2) the mechanisms behind their effects and 3) the influence of 
diabetes on the cardioprotective effects.
Study I. Arginase inhibition by N-omega-hydroxy-nor-L-arginine (nor-NOHA) prior to 
reperfusion in rats subjected to myocardial IR reduced infarct size (IS). This effect was abolished 
by inhibition of NOS, protein kinase C epsilon (PKCε) and blocking of the mitochondrial ATP-
dependent potassium channel. The effect of nor-NOHA was associated with enhanced myocardial 
expression of PKCε.
Study II. Combined administration of L-arginine and BH4 before and during reperfusion 
reduced IS in rat and pig models of myocardial IR. At the same time individual administration 
of L-arginine or BH4 failed to evoke cardioprotection in both species. NOS inhibition abrogated 
the cardioprotective effect of L-arginine and BH4. Myocardial BH4 levels were higher in pigs 
given BH4 with or without L-arginine. The generation of superoxide in the ischemic-reperfused 
myocardium was reduced only in pigs treated with the combination of L-arginine and BH4.
Studies III-IV. Pharmacological enhancement of peroxynitrite decomposition and inhibition 
of ROCK protected from IR injury and attenuated myocardial ROCK and arginase activity in 
rats subjected to IR. Rats with type 1 diabetes had increased myocardial arginase activity, 
arginase 2 expression and ROCK activity. In addition, ROCK and arginase inhibition protected 
against myocardial IR in rats with type 1 diabetes. RIPerc induced by bilateral femoral artery 
occlusion resulted in reduction of IS, myocardial peroxynitrite formation, ROCK and arginase 
activity and upregulated myocardial endothelial NOS. The cardioprotective effect of RIPerc and 
associated changes in arginase and ROCK activity were absent in rats with type 1 diabetes. The 
cardioprotective effects of RIPerc, ROCK and arginase inhibition were abolished by inhibition of 
NOS.
Conclusions. Inhibition of arginase before the onset of reperfusion reduced IS via a mechanism 
dependent on NOS activity, PKCε expression and activation of mitochondrial ATP-dependent 
potassium channels. Supplementation of L-arginine and BH4 during late ischemia and reperfusion 
reduced IS via a NOS-dependent pathway and reduced the generation of superoxide. Peroxynitrite 
and ROCK signaling pathways are involved in the upregulation of arginase activity during 
myocardial IR. Inhibition of either ROCK or arginase protected against myocardial IR injury via a 
NOS–dependent mechanism both in the presence and absence of type 1 diabetes. This suggests that 
reduction in arginase activity, as a result of reduced formation of peroxynitrite and ROCK activity, 
is of importance for the NOS-dependent cardioprotective effect of RIPerc. The cardioprotective 
effect of RIPerc and associated signaling effects on arginase, ROCK and NOS are abolished in 
type 1 diabetes. Arginase inhibition, supplementation of BH4 and L-arginine, inhibition of ROCK 
and RIPerc are potential tools in the treatment of acute myocardial infarction.
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LIST OF ABBREVIATIONS
5-HD 5-hydroxydecanoic acid sodium (mitoKATP channel blocker)
AAR area at risk
BH2 dihydrobiopterin
BH3 trihydrobiopterin
BH4 tetrahydrobiopterin
CAD coronary artery disease
FeTPPS 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron (III), 
chloride (ONOO-  decomposition catalyst)
cGMP cyclic guanosine monophosphate
eNOS endothelial nitric oxide synthase
ε-V1-2 specific PKCε inhibitor
HR heart rate
im intramuscular
iNOS inducible nitric oxide synthase
ip intraperitoneal
IR ischemia-reperfusion
IS infarct size
iv intravenous
LAD left anterior descending artery
L-NMMA NG-monomethyl-L-arginine monoacetate (NOS inhibitor)
MAP mean arterial pressure
mitoKATP channel mitochondrial adenosine triphosphate dependent potassium 
channel
nNOS neuronal nitric oxide synthase
NO nitric oxide
nor-NOHA N-omega-hydroxy-nor-L-arginine (arginase inhibitor)
NOS nitric oxide synthase
O2- superoxide 
ONOO- peroxynitrite
PCI percutaneous coronary intervention
PKCε protein kinase C epsilon
PKG protein kinase G
RIC remote ischemic conditioning
RIPerc remote ischemic perconditioning
RIPostc remote ischemic postconditioning 
RIPrec remote ischemic preconditioning
ROCK RhoA/Rho-associated kinase
ROS reactive oxygen species
sGC soluble guanylyl cyclase
TTC triphenyltetrazolium chloride
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INTRODUCTION
Myocardial ischeMia-reperfusion injury
Myocardial infarction is a cause for millions of new mortality and morbidity cases occurring 
worldwide each year (White and Chew, 2008; Hausenloy and Yellon, 2013). Diagnosis and 
treatment of acute myocardial infarction have reached substantial progress over the last 
decades resulting in improved outcomes and prognosis for the patients. However, despite 
timely applied primary percutaneous coronary intervention (PCI), a significant number of 
patients die or develop heart failure (Bulluck et al., 2015).
Occlusion of a coronary artery leads to myocardial ischemic injury which is characterized 
by a switch to anaerobic respiration in absence of oxygen, adenosine triphosphate depletion, 
depolarization of mitochondrial membrane, reduction of intracellular pH and ionic imbalance 
between the cells and extracellular space (Avkiran and Marber, 2002). The current strategy 
for treating acute myocardial infarction caused by coronary artery occlusion is aimed at rapid 
and effective reperfusion which minimizes myocardial damage (Hausenloy and Yellon, 2013). 
Early restoration of blood flow by means of primary PCI and thrombolytic therapy rescues 
the myocardium at risk and limits infarct size (IS). However, reperfusion may itself induce 
additional myocardial injury and is therefore characterized as a “double-edged sword”. The 
rescue of ischemic myocardium is inevitably accompanied by hazardous alterations and 
death of cardiomyocytes (Braunwald and Kloner, 1985; Piper et al., 1998; Hausenloy and 
Yellon, 2013). Reperfusion injury is characterized by oxidative stress (Zweier et al., 1987), 
intracellular calcium overload (Miyamae et al., 1996), prompt change of pH (Lemasters et 
al., 1996), opening of mitochondrial permeability transition pore (Heusch et al., 2010), 
activation of inflammatory processes, immune response and dysfunction of the microvascular 
endothelium (Turer and Hill, 2010). Thus, development of novel treatments that limit the 
extent of the reperfusion injury will have substantial impact on IS and myocardial function 
following an acute myocardial infarction. Reperfusion injury has therefore gained considerable 
interest as a target for myocardial salvage and in the design of novel therapeutic strategies. The 
pathophysiology of ischemia and reperfusion in the heart created by restoration of blood supply 
to the jeopardized myocardium, are often described together as the phenomenon of myocardial 
ischemia-reperfusion (IR) injury. The development of appropriate therapeutic strategies 
protecting against myocardial IR injury by targeting its pathophysiological mechanisms is 
expected to be of clear clinical benefit.
nitric oxide in regulation of cardiovascular function
Nitric oxide (NO) is a key regulator of vascular tone, inhibitor of platelet adhesion and 
aggregation, modulator of smooth muscle cell proliferation and its adequate basal synthesis 
is crucial for proper cardiovascular function (Moncada and Higgs, 2006). The synthesis of 
NO is performed by the enzyme nitric oxide synthase (NOS), which exists in three isoforms: 
neuronal (nNOS), expressed constitutively in neurons; inducible (iNOS), expressed in 
macrophages in response to immunological stimulation by cytokines; endothelial (eNOS), 
expressed constitutively in endothelial cells (Moncada and Higgs, 2006). Expression and 
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activation of iNOS are observed in neoplasms, during infections and inflammation (Kröncke 
et al., 1998) and are of minor importance under physiological conditions. The most important 
physiological effects of nNOS include the regulation of neuronal communication and the 
release of neurotransmitters in the nervous system (Zhao et al., 2015). It should be noted that 
nNOS is also expressed in cardiomyocytes (Xu et al., 1999), smooth muscle cells (Boulanger 
et al., 1998) and endothelial cells (Bachetti et al., 2004). It has been shown that nNOS-derived 
NO participates in regulation of vascular tone independently from eNOS (Ichihara et al., 1998). 
However, eNOS is the most crucial isoform involved into the regulation of cardiovascular 
function via synthesis of NO in endothelial cells (Förstermann and Sessa, 2012; Zhao et al., 
2015).
 
NO is synthesized in endothelial cells by eNOS from the substrate L-arginine (Palmer et al., 
1988) (Figure 1). The production and release of endothelium-derived NO is stimulated by 
several factors, including shear stress (Andrews et al., 2010), acetylcholine (Kellogg et al., 
2005), bradykinin (Bae et al., 2003), histamine (Kishi et al., 1998) and other organic chemicals. 
NO produced by endothelial cells exerts constitutive vasodilating (Figure 1) effect (Furchgott, 
1988) via stimulation of soluble guanylate cyclase (sGC) in the vascular smooth muscle cells, 
Figure 1. Roles of arginase, RhoA/Rho-associated kinase, L-arginine, tetrahydrobiopterin and 
principal pathophysiological stimuli for endothelial NO availability and cardiovascular function. BH2 – 
dihydrobiopterin; BH3 – trihydrobiopterin; BH4 – tetrahydrobiopterin; eNOS – endothelial nitric oxide 
synthase; LDL – low-density lipoprotein; LPS – lipopolysaccharide; mitoKATP – mitochondrial adenosine 
triphosphate dependent potassium channel; NO – nitric oxide; O2- – superoxide; ONOO- – peroxynitrite; 
PKC – protein kinase C; PKCε – protein kinase C epsilon; PKG – protein kinase G; ROS – reactive oxygen 
species; sGC – soluble guanylyl cyclase; VSMC – vascular smooth muscle cell.
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leading to the formation of cyclic guanosine monophosphate (cGMP), which in turn stimulates 
protein kinase G (PKG)-mediated intracellular calcium depletion, resulting in the relaxation of 
smooth muscle (Zhao et al., 2015). In addition to vessel relaxation, NO inhibits apoptosis (Li et 
al., 1999), reduces neutrophil adherence to the vascular endothelium (Ma et al., 1993), prevents 
platelet aggregation (Walter and Gambaryan, 2009), scavenges superoxide (O2
-) (McCall 
et al., 1989), suppresses the proliferation of vascular smooth muscle cells (D’Souza et al., 
2003). In cardiomyocytes NO induces the opening of mitochondrial adenosine triphosphate-
dependent potassium channel (mitoKATP channel) via the activation of sGC, PKG and protein 
kinase C epsilon (PKCε) (Costa and Garlid, 2008) (Figure 1). The activation of mitoKATP 
channel leads to reduced anoxic cell injury due to restoration of a membrane potential (Xu 
et al., 2001). However, not all the effects of NO depend on sGC and cGMP/PKG pathway. 
Another mechanism of action involves reaction of NO or its derivatives with cysteine residues 
of target proteins, referred to as S-nitrosylation (Stamler et al., 2001). Unlike sGC signaling, 
S-nitrosylation requires higher concentrations of NO, and is among other processes implicated 
in apoptosis, proliferation and secretion of protein and in the regulation of NOS activity (Qian 
and Fulton, 2013). 
The regulation of eNOS expression and activity and therefore control of NO production are 
performed at the transcriptional, posttranscriptional and posttranslational levels (Qian and 
Fulton, 2013). Posttranslational mechanisms cause urgent changes in eNOS activity and 
are crucial for the normal function of NO pathways. The regulation of eNOS activity at the 
posttranslational level includes availability of enzyme substrate and co-factors, phosphorylation, 
S-nitrosylation, acylation of fatty acids and interactions between proteins (Qian and Fulton, 
2013). Similarly to the other NOS isoforms, eNOS is a monomer and needs to organize as a 
dimer in order to catalyze the production of NO (Rafikov et al., 2011). Stability of the dimeric 
form (coupling) is maintained by optimal cellular concentrations of the substrate L-arginine 
and the co-factor tetrahydrobiopterin (BH4) which plays a fundamental role in the production 
of NO in endothelial cells (Rafikov et al., 2011; Förstermann and Sessa, 2012) (Figure 1). 
In contrast to that, the uncoupled (monomeric) form of eNOS is unable to produce NO and 
generates O2
- instead (Förstermann and Sessa, 2012) (Figure 1). Phosphorylation of various 
eNOS sites via protein kinases is involved in regulation of its activity. Thus, phosphorylation 
of human isoforms of serine residue Ser1177 or threonine residue Thr495 results in increase or 
decrease of eNOS activity, respectively (Qian and Fulton, 2013). However, dephosphorylation 
is mediated by phosphatases and causes an opposite effect (activation of eNOS after Thr495 
dephosphorylation). S-nitrosylation is a feedback instrument to downregulate eNOS activity 
by targeting enzymes cysteine residues with NO when its concentrations are high (Lima et al., 
2010). Fatty acids acylation mediates subcellular distribution of eNOS (Qian and Fulton, 2013). 
The activity of eNOS can be modulated via its binding to the other proteins. The activation 
of eNOS occurs after interaction with calmodulin or heat shock protein 90 (Förstermann et 
al., 1991; Garcia et al., 1998). In contrast, binding to caveolin-1, NOS interacting protein or 
NOS traffic inducer promote decrease of eNOS activity (Smart et al., 1999; Dedio et al., 2001; 
Zimmermann et al., 2002).
Accordingly, the normal function of cardiovascular system requires optimal availability of 
endothelium-derived NO, which is determined not only by expression of eNOS, but is strictly 
dependent on posttranslational machinery of enzyme activity regulation. 
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nitric oxide availability in vascular dysfunction and 
Myocardial ischeMia-reperfusion injury
Several risk factors contribute to the vascular dysfunction and the development of coronary 
artery disease (CAD), which includes angina pectoris, sudden cardiac death and myocardial 
infarction (Wong, 2014). Those risk factors affect the cardiovascular system via substantially 
impaired endothelial function due to reduction of NO availability (Su, 2015).
Factors generating endothelial dysfunction
Atherosclerosis is the underlying cause of the majority of CAD cases. This chronic disease is 
characterized by hypercholesterolemia, impaired vasodilation and progressive formation of 
atheromatous plaques in arteries, culminating in ischemic events caused by atherothrombosis. 
Hypercholesterolemia stimulates leukocytes adherence and adhesion of activated platelets, 
resulting in endothelial dysfunction. High concentrations of cholesterol in blood promote 
activation of oxidases and production of reactive oxygen species (ROS), which react with 
NO, decreasing its availability and forming reactive nitrogen species, which in turn contribute 
to uncoupling of eNOS and lack of NO production and release (Su, 2015). Diabetes mellitus, 
described as one of the most prominent risk factor for CAD, is accompanied by profound 
endothelial dysfunction driven by hyperglycemia-dependent generation of ROS, uncoupling 
of eNOS, platelet aggregation and increased expression of adhesion molecules and high 
incidence of apoptosis among endothelial cells (Su, 2015). Another risk factor of CAD is 
hypertension, which also involves uncoupling of eNOS, increased ROS production and low 
bioavailability of NO, leading to violated endothelium-dependent vasorelaxation (Landmesser 
et al., 2003). It is well-known that CAD has higher incidence among smokers and aged people. 
Tobacco smoke contains various reactive components which cause vascular endothelium-
dependent dysfunction via increased adherence of platelets and leukocytes, inflammatory 
response, oxidation, scavenging of NO by ROS and downregulation of eNOS activity through 
its uncoupling and altered phosphorylation (Messner and Bernhard, 2014). Ageing causes 
functional and structural changes in the vasculature including endothelial cells, which become 
sensitive toward apoptotic stimuli (Hoffmann et al., 2001). In addition, aged endothelial cells 
are characterized by low eNOS phosphorylation, uncoupling of eNOS and increased ROS 
production (Su, 2015).
Thus, all major risk factors which contribute to the development of CAD and particularly 
myocardial infarction, are associated with decreased availability of NO and endothelial 
dysfunction. As mentioned previously, ischemia of the heart in subjects with myocardial 
infarction, followed by restoration of blood supply to the ischemic region, contribute together to 
the myocardial IR injury. Myocardial ischemia stimulates endothelial dysfunction and further 
reduction of available NO (Giraldez et al., 1997). Myocardial ischemia downregulates eNOS 
expression and leads to tissue acidosis, attenuating the activity of eNOS (Giraldez et al., 1997). 
Later on, successful reperfusion overloads previously ischemic myocardium with oxygen, 
which causes considerable generation of ROS, cell injury, uncoupling of eNOS and decrease 
of its activity below basal physiological level (Amrani et al., 1995). Reduced endothelial 
NO availability triggers platelet aggregation, expression of cytokines, activation of adhesion 
molecules and adherence of the leukocytes to the endothelium, increased vascular permeability 
and migration of the various inflammatory cells into the myocardium and activation of iNOS, 
which synthesizes high amounts of toxic NO, all contributing  to further tissue damage (Darra 
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et al., 2010; Turer and Hill, 2010). Myocardial vasculature is deprived of basal NO production 
in endothelial cells, and microvascular tone shifts, accordingly, to vasoconstriction impairing 
perfusion (Pagliaro et al., 2003).
Clinical data indicate that the diabetic heart compared to the non-diabetic is more sensitive 
to IR injury. Patients with diabetes have an increased risk of ischemic events (Galiñanes and 
Fowler, 2004). Diabetes is an important risk factor for unfavorable outcomes after coronary 
revascularization (Galiñanes and Fowler, 2004). The negative influence on cardiovascular 
function in diabetes is caused by hyperglycemia, oxidative stress, inflammation, dyslipidemia 
and reduced NO bioavailability (Guerci et al., 2001; Creager et al., 2003). Diabetes alters 
neutrophil adhesion, promotes dysfunction of endothelial cells and myocytes, impairs function 
of eNOS and affects metabolic processes in the myocardium, thereby augmenting the degree 
of injury following myocardial IR (Galiñanes and Fowler, 2004).
Alterations of endothelial function during myocardial IR injury complicated by diabetes, as 
well as in patients without diabetes, emphasize the importance of treatment approaches which 
aim to recover the availability of NO in order to minimize the damage of myocardium. It has 
been proposed that maintenance of NO levels close to the normal homeostatic range can be 
fruitful for the heart facing the challenge of IR injury (Darra et al., 2010). It is considered 
that therapeutic strategies that are able to reverse eNOS uncoupling can consequently exert 
beneficial effects on NO availability and improve cardiovascular function (Förstermann and 
Sessa, 2012). 
It was noted previously, that optimal cellular concentrations of the substrate L-arginine and the 
co-factor BH4 are important for eNOS coupling. Therefore, mechanisms of their deficiency and 
approaches to eliminate their limitations in the setting of myocardial IR should be considered.
The role of arginase and RhoA/Rho associated kinase for nitric oxide availability
L-arginine is not only a substrate for all the NOS isoforms, but is also a substrate for the 
enzyme arginase which hydrolyzes L-arginine to L-ornithine and urea (Durante et al., 2007) 
and thereby competes with NOS which converts L-arginine to NO and L-citrulline (Figure 1). 
Arginase is expressed in two isoforms: cytosolic arginase 1 and mitochondrial arginase 2 (Ash 
et al., 2000). Arginase 1 plays an important role in the hepatic urea cycle for the disposal of 
ammonia. Both arginase 1 and arginase 2 are expressed in endothelial cells, vascular smooth 
muscle cells and cardiomyocytes in different species (Pernow and Jung, 2013). Possible 
differences in the functioning of the two isoforms of arginase in the cardiovascular system 
remain unclear due to the absence of isoform-specific arginase inhibitors. Activation of 
arginase leads to reduced availability of L-arginine which results in decreased NO production 
and contributes to endothelial dysfunction. Decreased availability of L-arginine induced by 
arginase leads to uncoupling of eNOS resulting to production of O2
- instead of NO by NOS and 
formation of peroxynitrite (ONOO-), which in turn can contribute to oxidation of the eNOS 
co-factor BH4 (Förstermann and Sessa, 2012).
 
Factors which provoke increased expression of arginase include bacterial endotoxins 
(lipopolysaccharides), cytokines, oxidized low-density lipoproteins, glucose, angiotensin 
II, hypoxia, ROS and thrombin (Pernow and Jung, 2013) (Figure 1). These factors activate 
various intracellular kinases (Figure 1), including protein kinase C/RhoA/Rho kinase (ROCK) 
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pathway, cyclic adenosine monophosphate/protein kinase A pathway, mitogen-activated protein 
kinase and tyrosine kinase (Pernow and Jung, 2013). However, as for other enzymes, another 
functional determinant of the arginase along with expression is its activity. The activity of 
endothelial arginase is increased via the ROCK pathway by oxidized low-density lipoproteins 
(Ryoo et al., 2011; Pandey et al., 2014) or by thrombin (Ming et al., 2004). Moreover, it was 
shown that ROS increase arginase activity in endothelial cells through the ROCK pathway 
(Chandra et al., 2011) (Figure 1). 
Numerous studies demonstrated that arginase expression and activity are increased in 
conditions associated with endothelial dysfunction and decreased availability of NO, including 
atherosclerosis (Ryoo et al., 2011; Thengchaisri et al., 2006), hypertension (Demougeot et al., 
2007; Zhang et al., 2004), ageing (Berkowitz et al., 2003), smoking (Sikka et al., 2013) and in 
myocardial IR (Hein et al., 2003; Jung et al., 2010). Diabetes is also an important risk factor for 
complications in myocardial IR which is accompanied by upregulated expression and activity 
of arginase in the aorta (Romero et al., 2008; Grönros et al., 2011), myocardium (Grönros et al., 
2011), corpora cavernosa (Toque et al., 2011), retinal endothelium (Elms et al., 2013) and the 
endothelium of coronary arterioles (Beleznai et al., 2011). In addition, the enhancement of the 
ROCK pathway is involved in endothelial dysfunction in aorta from the diabetic rats (Cicek et 
al., 2013). The importance of ROCK for upregulation of arginase in diabetes was supported by 
deletion of ROCK in diabetic knock-out mice, which attenuated aortic endothelial dysfunction 
and prevented increased arginase activity and expression, restoring availability of NO (Yao et 
al., 2013).
 
Therefore, arginase inhibition and ROCK inhibition seem to be effective targets to attenuate 
uncoupling of eNOS, increase NO availability and prevent the formation of O2
- and ONOO-. 
Indeed, arginase inhibition reverses uncoupling of NOS and improves endothelial function 
in atherosclerosis (Ryoo et al., 2008), hypertension (Bagnost et al., 2010) and in ageing 
(Kim et al., 2009). It has been shown that the inhibition of arginase reverses impaired 
endothelium-dependent vasodilation in coronary arteries from rats with type 1 diabetes 
(Romero et al., 2008). A clinical study in patients with CAD and type 2 diabetes demonstrated 
improved endothelium-dependent vasodilatation in the forearm after local infusion of the 
arginase inhibitor N-omega-hydroxy-nor-L-arginine (nor-NOHA) (Shemyakin et al., 2012). 
Administration of nor-NOHA restored coronary microvascular function in diabetic rats via 
increased NO availability (Grönros et al., 2011), suggesting a potential cardioprotective ability 
of arginase inhibition in the setting of myocardial IR, especially in a condition complicated 
by co-morbidity such as diabetes. Previous studies showed that pretreatment of non-diabetic 
rats with nor-NOHA before the coronary artery occlusion resulted in significant reduction in 
IS after 30 min of ischemia and 2 h of reperfusion (Jung et al., 2010). Local infusion of nor-
NOHA into the coronary artery of pigs during late ischemia and early reperfusion also reduced 
IS (Gonon et al., 2012). However, the mechanisms underlying the cardioprotective effect of 
arginase inhibition in a clinically relevant setting in connection with the onset of reperfusion, 
as well as the possibility to obtain protective effects of arginase inhibition in myocardial IR 
complicated by diabetes have remained unexplored. In addition, it was reported that ROCK 
inhibition significantly decreased IS in the non-diabetic rats via downregulation of the ROCK 
pathway (Bao et al., 2004; Li et al., 2012) and effectively improved coronary vascular function 
in the type 1 diabetic rats in vivo (Pearson et al., 2013). These observations along with the 
recently described activation of arginase in endothelial cells via the ROCK pathway suggest 
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an intriguing possibility to increase NO availability in ischemic-reperfused myocardium in 
diabetes by downregulation of arginase via ROCK inhibition.
The role of tetrahydrobiopterin for nitric oxide availability
Another mechanism for the uncoupling of NOS and impaired cardiovascular function is a 
lack of the essential co-factor BH4 (Crabtree and Channon, 2011). Low availability of BH4 is 
associated with impaired endothelial function and decreased production of NO in atherosclerosis 
(Tiefenbacher et al., 2000), CAD (Maier et al., 2000), diabetes (Shinozaki et al., 2000) and 
smoking (Heitzer et al., 2000). Oxidative stress associated with myocardial IR (Amrani et 
al., 1995) leads to BH4 oxidation by ROS and consequent formation of trihydrobiopterin 
(BH3) and dihydrobiopterin (BH2), resulting in eNOS uncoupling (Crabtree and Channon, 
2011) (Figure 1). It is remarkable that not only the depletion of BH4, but also the concurrence 
between BH2 and BH4 for binding with eNOS contributes to its uncoupling (Crabtree and 
Channon, 2011). In a setting of myocardial IR, BH4 deficiency contributes to myocardial 
injury and impaired cardiac contractility (Moens et al., 2011). Exogenous administration 
of the BH4 precursor sepiapterin or a synthetic analogue of BH4 restored the response to 
endothelium-dependent vasodilators in pig coronary arterioles isolated from hearts subjected 
to IR (Tiefenbacher et al., 1996). The diminished NO production in the ischemic heart ex vivo 
is associated with depletion of BH4 in the myocardium, and administration of exogenous BH4 
restored NO production and improved recovery of coronary flow (Dumitrescu et al., 2007). 
Intravenous administration of BH4 prior to ischemia significantly reduced myocardial IS in 
rats subjected to IR (Wajima et al., 2006). Moreover, the administration of BH4 or sepiapterin 
resulted in protection against IR injury in the liver (Hara et al., 2006), skeletal muscle (Wang 
et al., 2007) and kidney (Legrand et al., 2011). Importantly, BH4 attenuated liver IR injury 
when administered iv during ischemia before the onset of reperfusion (Hara et al., 2006). 
However, it is not known whether BH4 exerts cardioprotective effects in a clinically relevant 
model with administration during ischemia shortly before reperfusion. Of additional interest is 
the interaction between L-arginine and BH4 in the regulation of proper NOS function. Besides 
the role of BH4 in binding of L-arginine to NOS, L-arginine has proved to increase the levels 
of BH4 bound to NOS indicating that L-arginine supply is also crucial for NOS coupling 
(Gorren et al., 1996). This suggests a synergistic effect of L-arginine and BH4 in the setting of 
the reduced NO availability. Accordingly, the combination of L-arginine and BH4 decreased 
endothelial dysfunction induced by forearm IR in patients with type 2 diabetes mellitus and 
CAD (Settergren et al., 2009). However, the efficiency of combined administration of BH4 and 
L-arginine in a setting of myocardial IR injury remains to be assessed.
reMote ischeMic conditioning and nitric oxide availability 
in Myocardial ischeMia-reperfusion injury
Importantly, not only pharmacological approaches can cause favorable effects on the heart 
challenged by IR. Thirty years ago Murry and co-authors (Murry et al., 1986) described the 
existence of endogenous cardioprotective mechanisms activated by means of short periods of 
myocardial ischemia and reperfusion prior to the long lethal ischemic episode of the heart. This 
phenomenon is known as local ischemic preconditioning and is characterized by a remarkable 
reduction in IS. However, this procedure is not feasible in the clinical setting since the patients 
arrive to hospital with ongoing myocardial ischemia. Further preclinical and clinical studies 
(Zhao et al., 2003; Thibault et al., 2008) revealed cardioprotective efficacy by short cycles of 
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ischemia and reperfusion within risk area of the heart during ongoing ischemia (local ischemic 
postconditioning). Interestingly, not only local ischemic conditioning can protect the heart 
from IR injury. The phenomenon of remote ischemic conditioning (RIC) which involves 
short episodes of ischemia and reperfusion in a remote vascular bed resulting in resistance to 
IR injury in the heart was further discovered. This was initially described as an intracardiac 
phenomenon of remote ischemic preconditioning (RIPrec) (Przyklenk et al., 1993). It was 
subsequently demonstrated that RIPrec in the mesenterium (Gho et al., 1996), kidney (Gho et 
al., 1996; Pell et al., 1998) and limb (Kharbanda et al., 2002) protected the heart from IR injury. 
However, RIPrec is not clinically feasible since it is initiated before the onset of ischemia. 
Therefore, protocols of the intermittent limb ischemia during ongoing myocardial ischemia 
(perconditioning, RIPerc) or after the onset of reperfusion (remote ischemic postconditioning, 
RIPostc) of previously ischemic myocardium were investigated. These techniques of RIC 
seem to be the most optimal in a clinical setting due to the simplicity of application which 
can be started before and/or in association with reperfusion without affecting the primary PCI 
procedure. Both RIPerc (Schmidt et al., 2007) and RIPostc (Andreka et al., 2007) significantly 
reduced IS in pigs. The first randomized clinical trial established that RIC started before primary 
PCI increased myocardial salvage in patients with acute ST elevation myocardial infarction 
(Bøtker et al., 2010). The mechanisms behind the transfer of the cardioprotective signals from 
a remote organ to the heart have generated much attention and include neuronal and humoral 
components. In addition, intracardiac transduction plays an important role in cardioprotection 
(Heusch et al., 2015). Several candidates mediating this transfer have been proposed. NO and 
eNOS are involved in the transfer and transduction of the cardioprotection evoked by RIC 
(Heusch et al., 2015). RIPrec by occlusion of the femoral artery in mice resulted in shear stress-
dependent release of eNOS-derived NO, its oxidation to nitrite, which reached the myocardium 
via the circulation was suggested to mediate the cardioprotective effect (Rassaf et al, 2014). In 
addition, the deletion of eNOS in knock-out mice or by pharmacological inhibition abolished 
the cardioprotective effects of RIPrec (Rassaf et al, 2014). RIPostc, in turn, attenuated 
myocardial IR injury in rabbits via an eNOS-dependent mechanism (Tanq et al., 2011). 
Interestingly, RIPerc reduced myocardial no-reflow after IR via downregulation of ROCK 
activity (Zhao et al., 2009). Considering that ROCK pathway is a potent activator of arginase, 
the possible involvement of arginase downregulation and further increase of NO availability 
in the cardioprotective effects of RIPerc may be suggested. Moreover, the efficiency of RIPerc 
to attenuate myocardial IR injury in the presence of diabetes is of importance considering the 
confounding effect of diabetes on upregulation of ROCK and arginase.
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AIMS
The present project was focused on the novel strategies of protection against myocardial IR 
injury via increased NO bioavailability.
The following specific aims were set:
1. To investigate the mechanism behind the protection against myocardial IR injury 
induced by arginase inhibition.
2. To investigate whether administration of L-arginine and BH4 before the onset and 
during reperfusion reduces IS.
3. To investigate whether the ROCK signaling pathway contributes to arginase 
upregulation during myocardial IR, and the involvement of this pathway in the 
cardioprotective mechanism of RIPerc.
4. To investigate whether inhibition of ROCK, inhibition of arginase and RIPerc 
protect from myocardial IR injury in type 1 diabetes and to identify the 
mechanisms behind these effects.
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MATERIAL AND METHODS
aniMal Models of Myocardial ischeMia-reperfusion
Rat model of myocardial ischemia-reperfusion (Studies I-IV)
The experiments were performed on male Sprague-Dawley rats (Charles-River, Sulzfeld, 
Germany). Animals were allowed to acclimate in the animal facility with food and water ad 
libitum for a minimum of 1 week after arrival before any experimentation. The rats (260-
400 g) were anesthetized with sodium pentobarbital (50 mg/kg, ip followed by continuous 
infusion of 5 mg/kg/h, iv) and fentanyl (30-100 µg/kg/h, iv, studies I and II). Animals were 
tracheotomized, intubated and ventilated with air by a rodent ventilator (55 strokes/min, 9 
mL/kg tidal volume). Rectal temperature was maintained at 37.5-38.5 °C by a heated operat-
ing table. The right carotid artery was cannulated and connected to a pressure transducer for 
the measurement of mean arterial pressure (MAP). Heart rate (HR) was determined from the 
arterial pressure curve. Hemodynamic parameters were continuously recorded on a personal 
computer equipped with PharmLab V5.0 software (AstraZeneca R&D, Mölndal, Sweden). 
The left jugular vein was cannulated for drug administration. The heart was exposed via a 
left thoracotomy and a ligature was placed around the left coronary artery in order to induce 
reversible occlusion of the vessel. After completion of the surgical preparation, the rats were 
stabilized for at least 15 min before randomized for inclusion into study groups. Myocardial 
ischemia was induced by tightening of the ligature around the left coronary artery. Successful 
occlusion was associated with cyanosis of the myocardial area at risk (AAR). Reperfusion 
was initiated after 30 min of ischemia by removal of the snare and was maintained for 2 h. 
Reperfusion was associated with disappearance of the cyanotic colour of the myocardium 
and appearance of arrhythmias. 
Pig model of myocardial ischemia-reperfusion (Study II)
Farm pigs (27–38 kg) were premedicated with tiletamine (1.5 mg/kg, im), zolazepam (1.5 
mg/kg, im) and medetomidine hydrochloride (0.06 mg/kg, im).  Anesthesia was induced by 
sodium pentobarbital (20 mg/kg, iv bolus, following 2-4 mg/kg/h, iv and fentanyl 0.05 mg/h, 
iv). Heparin (5000 IU/h, iv) was given continuously. Animals were intubated and mechanically 
ventilated with air and oxygen. Respiratory rate and tidal volume were adjusted to keep 
arterial blood pH, oxygen and carbon dioxide levels within the physiological range. Rectal 
temperature was kept at 39.0±0.2°C by means of a heated operating table. A central venous 
catheter was inserted into the right external jugular vein for drug and fluid administration. 
Another catheter was placed in the descending aorta via the right femoral artery for the 
determination of blood gases and measurement of arterial pressure via a pressure transducer. 
HR was determined from the arterial pressure curve. All variables were continuously recorded 
on a personal computer equipped with PharmLab V3.0 software (AstraZeneca R&D, 
Mölndal, Sweden). The heart was exposed via a sternotomy. A ligature was placed around 
the left anterior descending artery (LAD) at a position from which the distal third of the 
artery is occluded via tightening of the ligature. An ultrasonic probe (Transonic Systems Inc., 
New York, USA) was placed around the artery just proximal to the snare for measurement 
of coronary blood flow. The flow probe was connected to a Transonic 208 blood flow meter. 
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An additional catheter was introduced into the right femoral artery and a guide wire was 
advanced to the aortic arch under fluoroscopic control. A coronary angiography catheter was 
slid over the wire and placed into the left main coronary for local drug administration. After 
a post-surgery stabilization period of 30 min the pigs were subjected to myocardial ischemia 
by tightening the ligature around the LAD. Ischemia was maintained for 40 min followed by 
reperfusion for 4 h. 
rat Model of type 1 diabetes Mellitus
Male Sprague-Dawley rats of age 5-6 weeks were used in studies III and IV for the 
induction of type 1 diabetes mellitus. Type 1 diabetes was induced by a single injection of 
streptozotocin (STZ, 55 mg/kg) dissolved in sterile Dulbecco’s phosphate buffered saline 
in the tail vein under anesthesia with isoflurane mixed with oxygen. Only those rats with 
blood glucose levels >15 mmol/L 72 h after the STZ injection were considered to be diabetic 
and were included in the study. Healthy age matched rats received an iv injection of vehicle 
(Dulbecco’s phosphate buffered saline) and served as a non-diabetic control group. Blood 
glucose concentration was measured weekly by FreeStyle Lite blood glucose monitoring 
system (Abbot Diabetes Care Inc., CA, USA). The rats were provided with food and water 
ad libitum until used for further experiments four to five weeks after the injection of STZ.
experiMental protocols
Study I
In study I, two separate experimental protocols were used. In protocol 1 rats were randomized 
to one of the following treatment groups: 1) saline (400 μL for IS determination, n=10); 2) 
saline (400 μL, for determination of arginase activity, n=9); 3) the arginase inhibitor nor-
NOHA (100 mg/kg, n=8); 4) the NOS inhibitor NG-monomethyl-L-arginine monoacetate 
(L-NMMA, 10 mg/kg) followed by nor-NOHA (n=6) or 5) the mitoKATP channel blocker 
5-hydroxydecanoic acid sodium (5-HD, 10 mg/kg) followed by nor-NOHA (n=6).
In protocol 2 additional rats were randomized to one of the following treatment groups: 1) 
saline (n=13); 2) the arginase inhibitor nor-NOHA (100 mg/kg, n=10); 3) the specific PKCε 
inhibitor ε-V1-2 (3 mg/kg) followed by nor-NOHA (n=6); 4) ε-V1-2 only (n=4) or 5) sham 
group (the coronary ligature was not tightened and no compounds were administered; n=5). 
Saline and all substances were given iv as bolus injections at 15 min of ischemia except 
5-HD and ε-V1-2 which were injected iv at 10 min of ischemia. The dosages were based on 
previous studies (Deuse et al., 2010; Gourine et al., 2005; Jung et al., 2010). L-NMMA and 
5-HD have previously been shown not to affect IS per se (Fryer et al., 2001; Gonon et al. 
2000). Since the effect of ε-V1-2 on IS per se was less documented, it was administered to a 
separate group of animals subjected to myocardial IR.
Study II
Also in study II, two separate experimental protocols were used. In protocol 1, rats were 
randomized to one of the following treatment groups: 1) saline (400 μL, n=8); 2) the NOS 
co-factor BH4 (10 mg/kg) followed by L-arginine (100 mg/kg, n=6); 3) BH4 followed by 
saline (200 μL, n=6); 4) saline (200 μL) followed by L-arginine (n=6); and 5) the NOS 
inhibitor L-NMMA (10 mg/kg) followed by BH4 and L-arginine (n=6). All substances were 
given iv as bolus injections at 25 min of ischemia.
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In protocol 2 pigs were randomized to receive a local intracoronary infusion into the left 
main stem of either: 1) saline (n=6); 2) BH4 (0.03 mg/kg/min, n=6); 3) L-arginine (3.0 mg/
kg/min, n=6) or 4) the combination of L-arginine and BH4 (n=6). In addition a fifth group 
received a systemic infusion of the same doses of L-arginine and BH4 via the jugular vein 
(n=5). All infusions were started at 30 min of ischemia and were given for 30 min, i.e. until 
20 min of reperfusion, at a rate of 2 mL/min. After 40 min of ischemia LAD was reperfused 
for 4 h by removal of the ligature. The dosages were based on previous studies (Dumitrescu 
et al., 2007; Hara et al., 2006; Jung et al., 2010; Nakanishi et al., 1992; Pernow et al, 1994; 
Wajima et al., 2006).
Study III
Also in study III, two separate experimental protocols were used. In protocol 1, rats were 
randomized to one of the following groups: 1) control myocardial IR (no intervention during 
IR; n=10), 2) myocardial IR + RIPerc induced by bilateral femoral artery occlusion using 
vessels clamps during the last 15 min of myocardial ischemia (n=10), 3) administration 
of the NOS inhibitor L-NMMA just prior to RIPerc (10 mg/kg, iv n=6), 4) administration 
of the ROCK inhibitor hydroxyfasudil (0.5 mg/kg, iv, n=7) 20 min prior to myocardial 
ischemia, or 5) administration of the ONOO-  decomposition catalyst 5,10,15,20-tetrakis(4-
sulfonatophenyl)porphyrinato iron (III) chloride (FeTPPS, 10 mg/kg, iv, n=6) 10 min prior 
to reperfusion. 
In protocol 2, type 1 diabetic or age-matched non-diabetic rats were randomized to one of 
the following groups: 1) non-diabetic controls (myocardial IR with no intervention, n=6), 
2) non-diabetic rats subjected to myocardial IR + RIPerc (n=6), 3) diabetic rats with no 
intervention during myocardial IR (n=7) and 4) diabetic rats subjected to myocardial IR + 
RIPerc (n=6).
The dosage of drugs and duration of the femoral artery occlusion were based on previous 
studies (Basalay et al., 2012; Jung et al., 2010; Loukili et al., 2011; Utsunomiya et al., 2001). 
NOS inhibition has previously been demonstrated not to affect IS per se (Gonon et al. 2000).
Study IV
Also in study IV, two separate experimental protocols were used. In protocol 1, type 1 dia-
betic or age-matched non-diabetic rats were randomized to one of to the following treatment 
groups given iv 15 min prior to myocardial ischemia: 1) saline (n=5, non-diabetic rats; n=5, 
diabetic rats); 2) the ROCK inhibitor hydroxyfasudil (0.5 mg/kg; n=5, non-diabetic rats; n=5, 
diabetic rats); 3) the NOS inhibitor L-NMMA (10 mg/kg) followed by hydroxyfasudil (n=5, 
diabetic rats) or 4) L-NMMA only (n=4, diabetic rats). 
In protocol 2, type 1 diabetic or age-matched non-diabetic rats were randomized to one of 
the following treatment groups given iv 15 min prior to myocardial ischemia: 1) saline (n=7, 
non-diabetic rats; n=14, diabetic rats); 2) the arginase inhibitor nor-NOHA (100 mg/kg, n=8, 
non-diabetic rats; n=11, diabetic rats); 3) the NOS inhibitor L-NMMA (10 mg/kg) followed 
by nor-NOHA (n=7, diabetic rats).
deterMination of area at risk and infarct size
After 2 h of reperfusion in rats and 4 h of reperfusion in pigs the left coronary artery was re-
occluded and 2% Evans blue solution was injected iv (1.5 mL for rat and 50 mL for pig) to 
stain non-ischemic myocardium for the determination of the AAR. The rats were euthanized 
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by exsanguination and the pigs were sacrificed by iv injection of potassium chloride. The 
hearts were extracted. The atria and the right ventricle were removed. The left ventricle of 
the rat was frozen for 20 min (−20°C) and cut into ~1.5 mm thick slices perpendicular to the 
base–apex axis. The left ventricle of the pig was cut into ~1 cm thick slices perpendicular 
to the heart base–apex axis without prior freezing. The third slice (counting from the apex) 
was cut into the ischemic and non-ischemic parts and frozen and stored at -80°C until further 
analysis. All the other slices were weighed, scanned from both sides for the determination of 
the AAR and put in 1% triphenyltetrazolium chloride (TTC) solution for 15 min (slices from 
rat) or 10 min (slices from pig) at 37°C to distinguish viable myocardium from necrotic. After 
24 h of incubation in 4% formaldehyde slices from rats were scanned again from both sides, 
IS and AAR were determined by planimetry of computer images (Adobe Photoshop CS 2, 
Adobe Systems, San Jose, CA, USA). Left ventricular slices from pigs were scanned directly 
after incubation in 1% TTC solution and IS and AAR were determined by planimetry. IS was 
expressed in percent of AAR.
Myocardial arginase activity
Arginase activity was determined by using a colorimetric assay. The assay measures the urea 
production using α-isonitrosopropiophenone. Following homogenization and centrifugation 
of tissue samples, 50 μL of the supernatant was added to 75 μL of Tris-HCl (50 mmol/L, 
pH=7.5) containing 10 mmol/L MnCl2. The mixture was activated by heating for 10 min at 
56 °C. Each sample was then incubated at 37°C for 1 h with L-arginine (50 μL, 0.5 M, in 
Tris-HCl, pH=9.7). The reaction was stopped by adding 400 μl of an acid solution (H2SO4–
H3PO4–H2O=1:3:7). 25 µL of α-isonitrosopropiophenone (9% in ethanol) was added to the 
mixture and then heated at 100°C for 60 min. Arginase activity was calculated as µmol urea/
mg protein/h and expressed as fold change from the control group.
Myocardial rock activity
Activity of ROCK in myocardium was determined in studies III and IV by analyzing the 
extent of phosphorylation of ezrin (Thr567) by immunoblotting.
peroxynitrite forMation in MyocardiuM
Formation of ONOO- in myocardium was measured by the evaluation of the expression of 
3-nitrotyrosine – a specific marker of oxidation mediated by ONOO-. Immunoblotting was 
used to detect 3-nitrotyrosine expression.
iMMunoblotting 
Protein extraction from the left ventricular myocardial tissue samples was performed in ice 
cold lysis buffer containing 20 mM Tris (pH=7.8), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 
1% TritonX-100, 10% (w/v) glycerol, 10 mM NaF, 1 mM ethylenediaminetetraacetic acid, 
5 mM Na-pyrophosphate, 0.5 mM Na3VO4, 1 mg/mL leupeptin, 0.2 mM phenylmethyl 
sulfonyl fluoride, 1 mg/mL aprotinin and 1 mM benzamidine (study I and III) or RIPA 
buffer (study IV). The homogenates were centrifuged at 5000g (study I) or 10000g (study 
III and IV) for 20 min at 4°C and the concentration of protein in the supernatant in each 
aliquot was determined using a bicinchoninic acid protein assay kit (Pierce Biotechnology, 
Rockford, IL, USA). Protein extracts (10, 40 or 50 μg per lane) were loaded onto a 7.5% or 
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10 % SDS gels and separated by electrophoresis. Proteins were transferred to polyvinylidine 
fluoride or nitrocellulose membranes and Ponceau staining was used to confirm the efficiency 
of transfer and to visualize protein loading. In study I, membranes were blocked overnight 
at 4°C, and then probed with antibodies against PKCε (BD Transduction Laboratories, 
Franklin Lakes, NJ, USA). Proteins were visualized by enhanced chemiluminescence with 
ECL advance Western blotting detection kit (Amersham Biosciences, Amersham, UK) and 
quantified using densitometry and Quantity One 4.5.1 software (Bio-Rad Laboratories, 
Inc., Hercules, CA, USA). In studies III and IV, membranes were blocked for 1 h at room 
temperature and incubated overnight at 4 °C with primary antibodies against arginase 1 
and 2 (1:1000, Sigma Prestige Antibody, USA); phoshorylated eNOS (anti-phosphorylated 
Ser-1177; 1:1000; BD Pharmingen, USA), total eNOS (1:1000; ABR Affinity BioReagents, 
USA); 3-nitrotyrosine (1:1000; Abcam, UK) or phosphorylated ezrin (anti-phosphorylated 
Thr567, 1:1000, BD Pharmingen, USA). IRDye 800-conjugated goat anti-mouse IgG 
(1:12000, LI-COR Biosciences, USA), IRDye 800-conjugated goat anti-rabbit IgG 
(1:12000, 1:15000, LI-COR Biosciences, Lincoln, NE, USA) and IRDye 680 (1:10000, LI-
COR Biosciences, USA) were used as secondary antibody and bands were visualized using 
infrared fluorescence scanner (IR-Odyssey, LI-COR Biosciences, USA). Equal loading was 
confirmed by expression of GAPDH (1:5000, Sigma Aldrich, USA) or, for 3-nitrotyrosine, 
staining with Coomassie brilliant blue. Band densities were analyzed with Image Studio Lite 
Version 3.1 (LI-COR Biosciences, USA).
deterMination of tetrahydrobiopterin levels in 
MyocardiuM
Myocardial BH4 levels in left ventricular tissue samples from pigs (study II) were 
determined by HPLC followed by electrochemical and fluorescent detection. Tissue lysates 
were resuspended in phosphate-buffered saline (50 mM), pH 7.4, containing dithioerythritol 
(1 mM) and ethylenediaminetetraacetic acid (100 μM) and subjected to three freeze–thaw 
cycles. After centrifugation (15 min at 13000 rpm and 4°C), samples were transferred to new, 
cooled micro tubes and precipitated with cold phosphoric acid (1 M), trichloroacetic acid (2 
M) and dithioerythritol (1 mM). Samples were vigorously mixed and then centrifuged for 
15 min at 13000 rpm and 4°C. Samples were injected onto an isocratic high performance 
liquid chromatography system and quantified using sequential electrochemical detection 
(Coulochem III, ESA, Inc., North Sioux City, SD, USA). High performance liquid 
chromatography separation was performed using a 250 mm ACE C-18 column (Hichrom, 
Berkshire, UK) and a mobile phase comprised of sodium acetate (50 mM), citric acid (5 
mM), ethylenediaminetetraacetic acid (48 μM), and dithioerythritol (160 μM, pH 5.2) (all 
ultrapure electrochemical high performance liquid chromatography grade) at a flow rate of 
1.3 mL/min. Background currents of +500 μA and −50 μA were used for the detection of 
BH4 on electrochemical cells E1 and E2, respectively. Quantification of BH4 was done by 
comparison with authentic external standards and normalized to sample protein content.
deterMination of superoxide production in MyocardiuM
Left ventricular myocardial tissue samples (size: 0.5×0.5×2.0 cm) were excised from the 
AAR following IR in pigs included into study II, and O2- production was determined 
using dihydroethidium (Sigma-Aldrich, St. Louis, MO, USA) fluorescence staining. The 
tissue blocks were embedded into cutting compound in optimal temperature and 20 μm 
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cryosections were produced in cryostat Leica CM3050 S (Leica Microsystems, Wetzlar, 
Germany), stained with dihydroethidium (1 μM), dissolved in phosphate-buffered saline 
solution (pH 7.4) and incubated at 37°C for 30 min in a dark humidified chamber. A negative 
control was obtained by blocking the reaction with N-acetyl-L-cysteine (100 mM, Sigma-
Aldrich, St. Louis, MO, USA). The fluorescent image was obtained using a fluorescence 
microscope Zeiss Axio Scope A1 (Carl Zeiss Microscopy GmbH, Jena, Germany) with a 
585 nm long-pass filter. The fluorescence intensities were determined using Image J software 
(NIH, Bethesda, MD, USA).
statistical analysis
Data were analyzed using GraphPad Prism 4.00 or 5.00 (GraphPad Software Inc., San Diego, 
CA, USA). Data are presented as mean±SEM. P-value <0.05 was considered statistically 
significant. In study I groups were compared using one-way ANOVA followed by Newman-
Keuls multiple comparison post-hoc test. Unpaired t-test was used for comparisons of only 
two groups. In study II groups were compared using Kruskal–Wallis test with Dunn’s 
multiple comparison test. In studies III-IV one-way ANOVA followed by Bonferroni 
post hoc test was used for multiple comparisons between several groups. Mann Whitney 
U-test was used for comparisons of only two groups where appropriate. Repeated-measures 
two-way ANOVA with Bonferroni post-hoc test was used for the multiple comparisons of 
hemodynamic parameters.
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RESULTS
MechanisMs of the cardioprotection induced by arginase 
inhibition (study i)
Hemodynamics
In comparison with the control group, there were no significant differences in MAP or HR 
except a lower HR in the group given 5-HD and nor-NOHA at 30 and 60 min of reperfusion 
and higher MAP at 60 min of reperfusion in the sham operated group. 
Area at risk and infarct size
There were no significant differences in the AAR between any of the groups in protocol 
1 and in protocol 2. Among animals included in protocol 1, IS in the control group was 
61±3 % (Figure 2). Arginase inhibition by nor-NOHA significantly reduced IS to 47±3 % 
(P<0.01). Administration of the NOS inhibitor L-NMMA or the mitoKATP channel blocker 
5-HD completely abolished the cardioprotective effect of nor-NOHA (Figure 2). In protocol 
2, it was established that administration of the PKCε inhibitor ε-V1-2 did not affect IS per se 
but it abolished the cardioprotective effect of the arginase inhibitor nor-NOHA (Figure 3).
Figure 2. Infarct size in rats subjected to 30 min of ischemia and 2 h of reperfusion. The rats were 
given either saline (vehicle, n=10), the arginase inhibitor nor-NOHA (n=8), nor-NOHA together 
with the NOS inhibitor L-NMMA (n=6), nor-NOHA together with the selective mitoKATP channel 
blocker 5-HD (n=6). Data are presented as mean ± SEM; *P<0.05; **P<0.01.
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Effect of ischemia-reperfusion on myocardial arginase activity
In order to evaluate the effect of IR on myocardial arginase activity, it was measured in 
ischemic and non-ischemic myocardium of animals given saline. Arginase activity in 
ischemic-reperfused myocardium was more than 2-fold higher than that in non-ischemic 
myocardium (Figure 4).
Figure 3. Infarct size in rats subjected to 30 min of ischemia and 2 h of reperfusion. The rats were 
given either saline (vehicle, n=13), the arginase inhibitor nor-NOHA (n=10), nor-NOHA together 
with the PKCε specific inhibitor ε-V1-2 (n=6) or ε-V1-2 only (n=4). Data are presented as mean ± 
SEM; **P<0.01
Figure 4. Arginase activity in non-ischemic (NI) and ischemic-reperfused (IR) myocardium of rats 
subjected to 30 min of ischemia and 2 h of reperfusion (n=9). Data are presented as mean ± SEM; 
*P<0.05.
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Effect of arginase inhibition on protein kinase C epsilon expression in ischemic-reperfused 
myocardium
Expression of PKCε was markedly reduced in ischemic-reperfused myocardium compared 
to non-ischemic myocardium of sham-operated animals. The expression of PKCε was 7-fold 
higher (P<0.01) in ischemic-reperfused myocardium of the rats treated with nor-NOHA than 
in those given vehicle (Figure 5).
cardioprotective effects of l-arginine and tetrahydro-
biopterin (study ii)
Hemodynamics
There were no significant differences in pre-ischemic hemodynamic parameters between the 
groups of rats or pigs. In rats HR was significantly higher before the onset and at the end 
of reperfusion in the group given L-arginine + BH4 than in the vehicle group. There were 
no statistical differences in hemodynamic parameters between the different groups of pigs 
during ischemia and reperfusion.
Figure 5. Representative immunoblots and quantification of the expression of protein kinase C epsilon 
(PKCε) in myocardium of sham-operated animals (n=5) and in ischemic-reperfused myocardium of 
rats subjected to 30 min of ischemia and 2 h of reperfusion, treated with vehicle (n=7) or nor-NOHA 
(n=7). Data are presented as mean ± SEM; **P<0.01; ***P<0.001. 
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Area at risk and infarct size
Both for rats and pigs there were no significant differences in AAR between the groups. 
In rats IS was 65±3 % in the vehicle group (Figure 6). IS was not significantly affected 
by administration of L-arginine (64±3 %) or BH4 (56±3 %) given separately. However, 
administration of the combination of L-arginine and BH4 resulted in a significant reduction of 
IS to 50±2 % (P<0.05 vs. the vehicle group). Administration of the NOS inhibitor L-NMMA 
abolished the protective effect of L-arginine and BH4 (IS 66±4 %).
In pigs IS was 86±5 % in the vehicle group (Figure 7). Neither infusion of L-arginine or 
BH4 alone affected IS significantly (77±5 % and 70±5 %, respectively). IS was significantly 
reduced by intracoronary administration of the combination of L-arginine and BH4 to 54±5 % 
(P<0.05 vs. the vehicle group). By contrast, systemic infusion of the same dose of L-arginine 
+ BH4 did not influence IS (83±6 %).
Myocardial tetrahydrobiopterin levels and superoxide production 
BH4 was determined in the myocardial AAR of pigs given intracoronary infusion of vehicle, 
BH4 or the combination of BH4 and L-arginine (Figure 8). Myocardial BH4 levels were 
significantly increased in animals given BH4 (5.4±2.6 pmol/mg) and BH4 + L-arginine 
(3.5±1.1 pmol/mg) in comparison with the vehicle group (0.9±0.3 pmol/mg). 
Formation of O2
- in the ischemic-reperfused myocardium of pigs determined by 
dihydroethidium staining was significantly lower in pigs given the combination of BH4 
and L-arginine than in vehicle treated pigs (Figure 9). L-arginine or BH4 alone did not 
significantly affect O2
- formation.
Figure 6. Infarct size in rats subjected to 30 min of ischemia and 2 h of reperfusion. The rats were 
given either saline (vehicle, n=8), BH4 with L-arginine (n=6), BH4 with vehicle (n=6), vehicle with 
L-arginine (n=6), the NOS inhibitor L-NMMA with BH4 and L-arginine (n=6). Data are presented as 
mean ± SEM; *P<0.05.
Yahor Tratsiakovich
26
Figure 7. Infarct size in pigs subjected to 40 min of ischemia and 4 h of reperfusion. The pigs were 
given either saline (vehicle, n=6), BH4 with L-arginine (n=6), BH4 alone (n=6) or L-arginine alone 
(n=6) by intracoronary (ic) infusion or BH4 with L-arginine by iv infusion (n=5). Data are presented 
as mean ± SEM; *P<0.05.
Figure 8. Tetrahydrobiopterin (BH4) levels in the ischemic-reperfused myocardium of pigs after 40 
min of ischemia and 4 h of reperfusion. The pigs were given either saline (vehicle, n=4), BH4 (n=6) 
or BH4 with L-arginine (n=4) by intracoronary infusion. Data are presented as mean ± SEM; *P<0.05. 
Significant differences versus the vehicle group are shown.
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rock signaling and arginase upregulation following 
Myocardial ischeMia-reperfusion: effects of reMote 
ischeMic perconditioning, rock inhibition and arginase 
inhibition on infarct size (study iii)
Area at risk and infarct size
There was no significant difference in the AAR between groups in protocol 1 of Study III. 
IS was significantly reduced by RIPerc, FeTPPS and hydroxyfasudil (42±4 %; 51±4 % and 
49±3 %, respectively) in comparison to the control group (69±2%, Figure 10A). The effect 
of RIPerc on IS was completely abolished by the NOS inhibitor L-NMMA (Figure 10A).
Effects of remote ischemic perconditioning, peroxynitrite decomposition and ROCK inhibition 
on arginase expression and activity in ischemic-reperfused myocardium
RIPerc, the peroxynitrite decomposition catalyst FeTPPS and the ROCK inhibitor 
hydroxyfasudil markedly suppressed arginase activity in ischemic-reperfused myocardium 
in comparison with the control group (Figure 10B, P<0.001). However, expression of 
arginase 1 and arginase 2 was not affected by any of the interventions. Arginase activity in 
non-ischemic myocardium of rats subjected to myocardial IR was not affected by RIPerc, 
FeTTPS or hydroxyfasudil.
Effects of remote ischemic perconditioning, peroxynitrite decomposition and ROCK inhibi-
tion on ROCK activity in ischemic-reperfused myocardium
RIPerc, FeTPPS and hydroxyfasudil suppressed the expression of  phosphorylated ezrin 
in ischemic-reperfused myocardium, indicating  significant reduction of ROCK activity in 
comparison with the control group following IR by a magnitude similar to that induced by 
the ROCK inhibitor (Figure 10C, P<0.001). The effect of RIPerc on ROCK activity was 
completely abolished by the administration of L-NMMA (Figure 10C).
Figure 9. Superoxide formation in the ischemic-reperfused myocardium of pigs after 40 min of ischemia 
and 4 h of reperfusion. The pigs were given either saline (vehicle, n=4), L-arginine (n=5), BH4 (n=4) or BH4 
with L-arginine (n=4) by intracoronary infusion. Data are presented as mean ± SEM; *P<0.05.
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Figure 10. Infarct size (A), arginase activity (B) and ROCK activity (C) in ischemic-reperfused myocardium of 
the rats subjected to 30 min of ischemia and 2 h of reperfusion. ROCK activity is expressed as phosphorylation 
of ezrin, representative immunoblots are shown. The rats were given either saline (vehicle, A: n=10, B: n=10, C: 
n=7), peroxynitrite decomposition catalyst FeTPPS (A: n=10, B: n=6, C: n=5), ROCK inhibitor hydroxyfasudil 
(H.fasudil, A: n=7, B: n=5, C: n=4), remote ischemic perconditioning (RIPerc, A: n=6, B: n=5, C: n=6), the 
NOS inhibitor L-NMMA with RIPerc (A: n=6, B: n=5, C: n=5). Data are presented as mean ± SEM; **P<0.01, 
***P<0.001 versus the vehicle group; ###P<0.001 versus the RIPerc group.
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Effect of remote ischemic perconditioning on myocardial peroxynitrite formation
The level of 3-nitrotyrosine, a marker of ONOO-  formation, in ischemic-reperfused 
myocardium was markedly attenuated by RIPerc (Figure 11).
Effect of remote ischemic perconditioning on myocardial eNOS expression 
Total eNOS and phosphorylated (Ser1177) eNOS were determined in the ischemic 
myocardium and the ratio of phosphorylated to total eNOS was calculated. RIPerc enhanced 
phosphorylation of eNOS at Ser1177 in ischemic-reperfused myocardium (Figure 12A). 
Figure 11. Peroxynitrite formation expressed as expression of 3-nitrotyrosine in ischemic-reperfused 
myocardium in rats subjected to 30 min of ischemia and 2 h of reperfusion. The non-diabetic (ND) rats were 
exposed to control myocardial ischemia-reperfusion (ND-control, n=8) or myocardial ischemia-reperfusion 
with remote ischemic perconditioning (ND-RIPerc, n=6). Representative immunoblots are shown. Data are 
presented as mean ± SEM; *P<0.05.
Figure 12. Representative immunoblots and ratio of the phosphorylated eNOS (p-eNOSSer1177) expression to 
total eNOS (t-eNOS) expression in myocardium of non-diabetic (A) and diabetic (B) rats subjected to 30 min of 
ischemia and 2 h of reperfusion. The non-diabetic (ND) and diabetic (DM) rats were exposed to control myocardial 
ischemia-reperfusion (ND-control, n=6; DM-control, n=6) or myocardial ischemia-reperfusion with remote 
ischemic perconditioning (ND-RIPerc n=6; DM-RIPerc, n=6). Data are presented as mean ± SEM; **P<0.01.
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influence of diabetes on cardioprotection induced by 
arginase inhibition, rock inhibition and reMote ischeMic 
perconditioning (studies iii-iv)
Matching of diabetic and non-diabetic rats
In Study III blood glucose level was 27.3±1.0 mmol/L four weeks after the administration 
of STZ compared to 4.9±0.2 mmol/L in the control group (P<0.001). Body weight was 
significantly lower in the group of rats with type 1 diabetes (291±12 g) than in the control 
group (394±9 g, P<0.001).
In the first part of the Study IV blood glucose was 28.8±0.4 mmol/L four weeks after the 
administration of STZ, compared to 4.5±0.1 mmol/L in the control group (P<0.001). Body 
weight was significantly lower in the diabetic group (278±8 g) than in the control group 
(386±6 g, P<0.001). 
In the second part of the Study IV blood glucose was 26.6±0.4 mmol/L four weeks after the 
administration of STZ, compared to 4.7±0.1 mmol/L in the control group (P<0.001). Body 
weight was significantly lower in the diabetic group (295±7 g) than in the control group 
(408±6 g, P<0.001).
 
There were no differences in blood glucose or body weight between the groups within the 
non-diabetic or diabetic rats, respectively.
Hemodynamics
HR was significantly lower in rats with type 1 diabetes in comparison with the non-diabetic 
controls (P<0.05). There were no significant differences in HR or MAP among non-diabetic 
or diabetic rats between the two parts of the study.
 
Effect of diabetes on myocardial ROCK activity, arginase expression and activity
The effect of diabetes on the activity of ROCK and arginase as well as expression of arginase 
isoforms was determined in the non-ischemic myocardium from diabetic and non-diabetic 
control groups in the Study IV. Both ROCK and arginase activity were significantly 
elevated in rats with diabetes in comparison with non-diabetic animals (Figure 13 A-B). 
There was no difference in arginase 1 expression between the two groups (Figure 13 C), 
whereas myocardial expression of arginase 2 was significantly increased in diabetic rats 
(Figure 13 D).  
Effect of remote ischemic perconditioning, arginase inhibition and ROCK inhibition on infarct 
size in diabetes
In protocol 2 of Study III, RIPerc reduced IS in non-diabetic rats from 68±2 % to 46±4 % 
(P<0.001). IS in rats with type 1 diabetes subjected to myocardial IR was 68±1 %. In contrast 
to non-diabetic rats, RIPerc failed to evoke cardioprotective effect in type 1 diabetic rats 
resulting in an unchanged IS (63±2 %) (Figure 14 A).
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In Study IV there were no significant differences in AAR between any of the groups. IS 
was comparable in the two parts of the study and it did not differ between diabetic control 
rats and non-diabetic controls. The ROCK inhibitor hydroxyfasudil significantly reduced 
IS by comparable magnitudes in diabetic and non-diabetic rats from 66±2% and 66±2% 
to 48±4% and 46±2%, respectively (P<0.001, Figure 15 A). Administration of the NOS 
inhibitor L-NMMA did not influence IS per se but abolished the cardioprotective effect of 
ROCK inhibition in diabetic rats (Figure 15 A).
Administration of nor-NOHA significantly reduced IS both in diabetic and non-diabetic rats 
from 67±3% and 68±3% to 51±3% and 45±4%, respectively (P<0.001, Figure 15 B). The 
NOS inhibitor L-NMMA abolished the cardioprotective effect of nor-NOHA in diabetic rats 
(Figure 15 B).
Figure 13. The effect of diabetes on activity of ROCK and arginase and the expression of arginase 
isoforms. (A) Expression of phosphorylated ezrin (p-ezrin) as a marker of ROCK activity, (B) 
arginase activity, (C) expression of arginase 1 and (D) arginase 2 in non-ischemic myocardium from 
non-diabetic (ND) and diabetic rats (DM) including representative immunoblots. Data are shown as 
mean±SEM; n=5-10; *P<0.05; **P<0.01.
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Figure 14. Infarct size (A), arginase activity (B, C) and ROCK activity (D, E) in ischemic-reperfused 
myocardium of non-diabetic (ND) rats and rats with type 1 diabetes mellitus (DM) subjected to 30 
min of ischemia and 2 h of reperfusion. ROCK activity is expressed as phosphorylation of ezrin, 
representative immunoblots are shown. The rats were exposed to control myocardial ischemia-
reperfusion (ND control, A: n=6, B: n=6, D: n=7; DM control, A: n=7, C: n=6, E: n=5) or myocardial 
ischemia-reperfusion with remote ischemic perconditioning (ND RIPerc, A: n=6, B: n=6, D: n=6; DM 
RIPerc, A: n=6, C: n=6, E: n=5). Data are presented as mean ± SEM; ***P<0.001 versus ND-control 
group; **P<0.01.
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Figure 15. Infarct size in rats subjected to 30 min of myocardial ischemia and 2 h of reperfusion.  
(A) The non-diabetic (ND) and diabetic (DM) rats were given either saline (vehicle; n=5, DM; 
n=5, ND); ROCK inhibitor hydroxyfasudil (H.fasudil; n=5, DM; n=5, ND); NO synthase inhibitor 
L-NMMA and hydroxyfasudil (n=5, DM) or L-NMMA only (n=4, DM). 
(B) The non-diabetic (ND) and diabetic (DM) rats were given either saline (vehicle, n=14, DM; n=7, 
ND); arginase inhibitor nor-NOHA (n=11, DM; n=8, ND) or the NO synthase inhibitor L-NMMA and 
nor-NOHA (n=7, DM). Data are presented as mean±SEM; *P<0.05; **P<0.01; ***P<0.001.
Effects of remote ischemic perconditioning on expression and activity of arginase, ROCK 
activity and phosphorylation of eNOS in ischemic-reperfused myocardium
Arginase activity in non-ischemic myocardium was increased by 48±11% (P<0.05) in rats with 
type 1 diabetes compared to non-diabetic controls. Arginase activity was increased by 70±20 
% and 87±11 % in ischemic myocardium in comparison with non-ischemic myocardium of 
rats with and without type 1 diabetes, respectively (P<0.01). RIPerc significantly reduced 
arginase activity in ischemic-reperfused myocardium of non-diabetic rats, but not in rats with 
type 1 diabetes (Figure 14 B-C). The expression of arginase isoforms was not affected by 
RIPerc in non-diabetic rats or in diabetic animals.
RIPerc failed to reduce ROCK activity in ischemic-reperfused myocardium of rats with 
diabetes in contrast to what was observed in non-diabetic rats (Figure 14 D-E).
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In contrast to the observation in non-diabetic rats, RIPerc failed to increase the expression 
of phosphorylated eNOS at Ser1177 in ischemic-reperfused myocardium of rats with type 1 
diabetes (Figure 12 B).
Effect of ROCK inhibition on arginase activity in ischemic-reperfused myocardium in diabetes
ROCK inhibition significantly attenuated myocardial arginase activity in diabetic rats 
following IR in the Study IV. The effect of ROCK inhibition on arginase activity was 
reversed by NOS inhibition (Figure 16).
Figure 16. The effect of ROCK inhibition on arginase activity following ischemia-reperfusion. 
Myocardial arginase activity in rats with diabetes mellitus subjected to control ischemia-reperfusion 
(DM control), ROCK inhibition by hydroxyfasudil (DM H.fasudil), the combination of NOS inhibition 
and ROCK inhibition (DM L-NMMA+H.fasudil), and NOS inhibition alone (DM L-NMMA). Data 
are presented as mean±SEM; n=4-5; **P<0.01; ***P<0.001.
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GENERAL  DISCUSSION
MechanisMs of protection against Myocardial ischeMia-
reperfusion injury induced by arginase inhibition
It is known that attenuated NO bioavailability related to endothelial dysfunction is an 
important mechanism behind the development of IR injury (Cohen et al., 2006) and that 
NO exerts cardioprotective effect (Sanada et al., 2011). L-arginine is a substrate not only for 
NOS, but also for arginase which converts L-arginine to L-ornithine and urea (Durante et al., 
2007). Increased arginase activity may thereby result in reduced formation of NO due to the 
competition between NOS and arginase for L-arginine. In addition, high activity of arginase 
is reported as a trigger of eNOS uncoupling and increased O2
- production (Kim et al., 2009) 
– factors which contribute to IR injury (Figure 17 A). 
The results of study I demonstrate in agreement with previous studies (Gonon et al., 2012; 
Jung et al., 2010) that arginase activity is increased in the myocardium following IR. 
Importantly, inhibition of arginase by nor-NOHA after the onset of ischemia but before the 
onset of reperfusion limits the extent of myocardial injury via a mechanism that involves 
production of NO. In agreement with previous studies (Gonon et al., 2012; Jung et al., 
2010), the involvement of NOS and its product NO in cardioprotection induced by arginase 
inhibition is confirmed by the suppression of cardioprotective effect by pretreatment with 
the NOS-inhibitor L-NMMA, which does not affect IS per se (Gonon et al., 2000). Although 
L-NMMA inhibits all the isoforms of NOS, the present data indicate that arginase inhibition 
increases the production of eNOS-derived NO since nNOS is not involved in the development 
of myocardial IR injury (Jones et al., 2000) and iNOS is not influenced in the brief protocol 
used in the study (Bulhak et al., 2006).
Previous studies have indicated that the cardioprotective effect of NO includes stimulation 
of cGMP, activation of PKG, PKCε and subsequent opening of the mitoKATP channel (Chai 
et al., 2011; Costa and Garlid, 2008; Sanada et al., 2001). Study I shows that arginase 
inhibition mediates cardioprotection via this signaling pathway. Thus, participation of 
PKCε in the mechanisms of the myocardial salvage was confirmed by the abolition of the 
cardioprotective effect of nor-NOHA by the PKCε specific inhibitor ε-V1-2. The inhibition 
of PKCε did not influence IS per se. In addition, study I showed remarkable downregulation 
of PKCε expression after IR. Interestingly, the administration of nor-NOHA maintained high 
expression of PKCε in the ischemic-reperfused myocardium. We further demonstrated that 
the selective mitoKATP channel blocker 5-HD completely blocked the cardioprotective effect 
of arginase inhibition by nor-NOHA indicating that its mechanism depends on the activation 
of mitoKATP channels. Previous studies established that 5-HD does not affect IS per se (Fryer 
et al., 2001). Collectively, the data provided in the present study indicate that arginase 
inhibition protects the myocardium from IR injury by increasing NO production, activation 
of PKCε followed by the activation of the mitoKATP channels (Figure 17 B).
Yahor Tratsiakovich
36
Figure 17. (A) Decrease in endothelial NO availability induced by myocardial ischemia-reperfusion and diabetes. 
(B) Restoration of endothelial NO availability by arginase inhibition, ROCK inhibition, supplementation of BH4 
and L-arginine or remote ischemic perconditioning (RIPerc). BH2 – dihydrobiopterin; BH3 – trihydrobiopterin; 
BH4 – tetrahydrobiopterin; eNOS – endothelial nitric oxide synthase; mitoKATP – mitochondrial adenosine 
triphosphate dependent potassium channel; NO – nitric oxide; O2- – superoxide; ONOO- – peroxynitrite; PKCε 
– protein kinase C epsilon; PKG – protein kinase G; ROS – reactive oxygen species; sGC – soluble guanylyl 
cyclase; VSMC – vascular smooth muscle cell. Arrows with solid lines – stimulation or production; dashed 
lines with perpendicular on the edge – inhibition.
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In study I nor-NOHA significantly reduced IS when administered systemically before the 
onset of reperfusion simulating a clinically relevant scenario. Therefore, this treatment may 
be effective when given in the clinical setting by iv administration in combination with 
revascularization in patients with ST-elevation myocardial infarction. The results obtained in 
a large animal study of myocardial IR and arginase inhibition before and during reperfusion 
show that local intracoronary administration of nor-NOHA significantly reduced IS in pigs 
(Gonon et al., 2012). Collectively, the available data suggest that both iv and intracoronary 
administration of an arginase inhibitor before the onset of reperfusion exerts clear 
cardioprotective effects in the setting of myocardial IR. These observations may form the 
basis for clinical studies to investigate the efficiency of arginase inhibition as a therapeutic 
strategy in patients with ST-elevation myocardial infarction.
role of l-arginine and tetrahydrobiopterin for the 
protection against Myocardial ischeMia-reperfusion 
injury.
Decreased availability of the NOS co-factor BH4 and the substrate L-arginine contribute to 
NOS uncoupling, resulting in low NO production and increased O2
- formation (Gorren et al., 
1996; Roe and Ren, 2012) (Figure 17 A). Previous studies have demonstrated that myocardial 
BH4 levels are reduced during ischemia due to oxidation which contributes to post-ischemic 
endothelial dysfunction (Dumitrescu et al., 2007) and that systemic pretreatment of rats with 
BH4 prior to ischemia results in cardioprotective effect in vivo (Wajima et al., 2006).
Study II shows in two animal models, that combined administration of L-arginine and BH4 
before and during reperfusion results in significant reduction of IS following myocardial 
IR. BH4 co-administered with L-arginine systemically to rats shortly before reperfusion 
evoked cardioprotective effect. In contrast, individual administration of either BH4 or 
L-arginine failed to reduce IS. The pig was included as a second experimental model in the 
study II since its cardiac anatomy and physiology is similar to the human heart (Hughes 
et al., 2003). Intracoronary infusion of substances via a catheter in the left main coronary 
artery resembles a clinical situation in patients with ST-elevation myocardial infarction 
undergoing primary PCI. Intracoronary infusion of the combination of BH4 and L-arginine 
starting before reperfusion significantly reduced IS. On the other hand, the same doses of 
BH4 and L-arginine infused systemically did not induce cardioprotection. This observation 
suggests that the cardioprotective effect of intracoronary infusion was mediated via a local 
effect in the ischemic-reperfused myocardium. In agreement with the data obtained in rats, 
individual administration of BH4 or L-arginine did not exert a significant cardioprotective 
effect in pigs. In contrast to previous data (Weyrich et al., 1992; Pernow et al., 2003), study 
II demonstrated that L-arginine administered proximally to the point of occlusion did not 
protect from IR injury. However, the results of the study II are in agreement with an earlier 
study in pigs in which systemic administration of L-arginine alone did not reduce IS (Gonon 
et al., 2011). The reason for the inefficiency of L-arginine in reducing IS may be due to 
increased metabolism by arginase, which is activated during IR (study I), and/or due to 
a decreased cellular uptake of L-arginine (Venardos et al., 2009). Administration of BH4 
alone did not reduce IS either when administered iv in rats or by intracoronary infusion in 
pigs, despite a clear increase in myocardial BH4 levels in pigs. In addition, only the combined 
administration of BH4 and L-arginine reduced myocardial O2
- accumulation in the pig study. 
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This observation indicates that the cardioprotective effect of BH4 and L-arginine was 
not achieved due to known antioxidant properties of BH4 (Mayahi, et al., 2007), but was 
attributed to the reversal of NOS uncoupling and the increase of NO availability achieved 
by the combined administration of BH4 and L-arginine (Figure 17 B). The involvement of 
NOS in the cardioprotective mechanisms of BH4 combined with L-arginine was confirmed 
by the finding that the NOS inhibitor L-NMMA abolished the reduction of IS in rats and pigs. 
the interaction between the rock pathway and arginase in 
Myocardial ischeMia-reperfusion
Activation of arginase during myocardial IR and the cardioprotective effect of arginase 
inhibition in the setting of IR have been reported using different protocols and animal models 
(Gonon et al., 2012; Jung et al., 2010; study I). These studies not only provided evidence 
for the cardioprotective efficacy of arginase inhibition, but also established its mechanisms 
using a diversity of pharmacological tools (inhibition of NOS and PKCε, NO scavenging, 
selective blocking of mitoKATP channel) and analysis of protein expression and enzyme 
activity. However, the upstream signaling regulating arginase in the ischemic-reperfused 
myocardium has remained unknown.
 
Study III demonstrated that ONOO- is an activator of ROCK which, in turn, stimulates the 
activity of arginase during myocardial IR. This was confirmed by the administration of the 
ONOO- decomposition catalyst FeTPPS which significantly reduced both ROCK and arginase 
activity as well as IS. The role of ROCK pathway in arginase activation was additionally 
confirmed by inhibition of ROCK with hydroxyfasudil (Figure 17 B) which reduced IS and 
myocardial arginase activity following IR. These results are in agreement with the previously 
reported activation of ROCK by ONOO- in endothelial cells and activation of endothelial 
arginase via the ROCK pathway (Chandra et al., 2012; Ming et al., 2004). In contrast to the 
activity of arginase, the expression of its isoforms was not changed significantly either after 
ONOO- decomposition or after ROCK inhibition, indicating that alterations in myocardial 
arginase activity are not dependent on its protein levels which is in accordance with previous 
observations (Gonon et al., 2012). 
the role of rock and arginase in cardioprotective effect 
of reMote ischeMic perconditioning
The additional aim of study III was demonstration of the cardioprotective effect of RIPerc 
and the involvement of ROCK and arginase for NO availability after RIPerc. Several 
experimental and clinical studies suggest that RIPerc is an effective therapeutic strategy to 
protect from IR injury (Schmidt et al., 2007; Bøtker et al., 2010). However, the mechanisms 
behind the transfer of the protection from the remote organ and the cardioprotective signaling 
within the myocardium are a matter of debate. Study III clearly showed the reduction 
of IS induced by RIPerc and that this effect was associated with decreased myocardial 
ROCK activity in accordance with the previous observation (Zhao et al., 2009). We further 
demonstrated diminished content of 3-nitrotyrosine in the ischemic-reperfused myocardium 
following RIPerc suggesting attenuated formation of the ROCK activator ONOO-. Of further 
importance, RIPerc evoked significant reduction of arginase activity in the myocardium at 
risk, which is in accordance with the established regulation of arginase activity via ONOO- 
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and ROCK in a setting of myocardial IR as described above. Finally, the involvement of 
increased NO availability in the cardioprotection, triggered by RIPerc was confirmed by the 
finding that pharmacological inhibition of NOS activity abolished the cardioprotective effect 
of RIPerc. The key role of eNOS in protection against IR injury by RIPerc was supported 
by the increased phosphorylation of eNOS after RIPerc. Collectively, the presented data 
suggest that RIPerc protects from IR injury via a mechanism that is dependent on production 
of eNOS-derived NO via a decrease in ROCK activity and arginase activity (Figure 17 B).
the iMportance of diabetes for cardioprotective effects 
in Myocardial ischeMia-reperfusion
Since patients with diabetes have an increased risk of ischemic events and high probability 
for unfavorable outcomes after coronary revascularization (Galiñanes and Fowler, 2004), 
it is of importance to investigate the therapeutic effects of cardioprotective strategies in 
diabetes. Based on the observations that diabetes is associated with elevated arginase activity 
and low availability of NO resulting in reduced endothelial function (Guerci et al., 2001; 
Romero et al., 2008), and that arginase is activated via the ROCK pathway in diabetes (Yao 
et al., 2013), we hypothesized that targeting of ROCK may be beneficial in myocardial IR in 
a model of diabetes as co-morbidity. Indeed, studies III and IV collectively demonstrated 
that induction of type 1 diabetes leads to elevated in ROCK and arginase activity, and 
increased expression of arginase 2 in non-ischemic myocardium. Similar to the observations 
in non-diabetic rats in study III, ROCK inhibition reduced IS in a magnitude comparable 
to the control animals without diabetes. The cardioprotective effect of the ROCK inhibitor 
was associated with a significant reduction of arginase activity in the ischemic-reperfused 
myocardium, supporting the role of ROCK in the regulation of arginase (Figure 17 B). 
Pharmacological inhibition of arginase by nor-NOHA in diabetic animals evoked significant 
decrease in IS to an extent comparable to that observed in rats without diabetes. The reduction 
of IS by both ROCK and arginase inhibition in diabetic rats was abolished by administration 
of the NOS inhibitor L-NMMA, confirming the involvement of increased NO availability in 
the mechanisms of cardioprotection induced by hydroxyfasudil or nor-NOHA. In addition, 
NOS inhibition prevented the decrease in myocardial arginase activity induced by the 
ROCK inhibitor in ischemic-reperfused myocardium of diabetic rats, indicating a shift of 
L-arginine consumption from NOS to arginase. A possible modification of arginase activity 
by L-NMMA per se is unlikely since administration of L-NMMA to diabetic rats subjected 
to myocardial IR did not affect arginase activity.
 
Study III demonstrated that the cardioprotection induced by RIPerc observed in non-diabetic 
animals was completely lost in animals with type 1 diabetes. These observations, which are 
in agreement with those previously reported for local preconditioning and postconditioning 
(Przyklenk, 2011), suggest that the diabetic heart is resistant to endogenous cardioprotective 
stimuli. It is established that diabetes impairs regulation of NOS signaling pathway (Tsang 
et al., 2005; Przyklenk, 2011) and that vascular dysfunction in diabetes is associated with 
elevated vascular and endothelial cell ROCK and arginase activity (Romero et al., 2008; 
Zhou and Li, 2012). In accordance with these observations, data from study III show that 
RIPerc did not phosphorylate myocardial eNOS and did not reduce myocardial ROCK 
activity and arginase activity during myocardial ischemia in diabetic rats. Thus, these data 
demonstrate that RIPerc, which induced marked reduction in IS in non-diabetic rats, failed 
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to reduce IS and to activate the cardioprotective signaling mechanisms in the presence of 
type 1 diabetes. This is in contrast to the successful cardioprotection against myocardial IR 
injury in type 1 diabetes obtained in study IV by pharmacological inhibition of either ROCK 
or arginase. Therefore, pharmacological inhibition of arginase or ROCK seems to be a more 
promising therapeutic strategy than RIPerc to reduce IS in the setting of diabetes.
liMitations
Certain limitations should be acknowledged regarding the studies included in this thesis. In 
all the studies open chest animal model of myocardial IR was used which, of course, could 
affect the results due to the inflammatory response following tissue damage. However, it is 
unknown whether effects of applied interventions differ between a clinically more relevant 
setting of closed chest from those obtained using the open chest model. The advantage 
with the open chest model is that coronary blood flow can be continuously monitored for 
confirmation of complete coronary artery ligation and successful reperfusion.
Most of the experiments were performed on relatively homogenous and young populations 
of laboratory animals. Most patients with ST-elevation myocardial infarction have one or 
several co-morbidities that may interfere with the cardioprotective treatment. In studies III 
and IV we therefore used animals with pathophysiological alterations caused by induction of 
type 1 diabetes and were able to demonstrate that this co-morbidity affects the results. More 
pronounced heterogeneity of the patients in clinical setting is expected to cause distinctions 
from the preclinical studies. There was no significant difference in the vulnerability to 
myocardial IR between type 1 diabetes and non-diabetic rats. This may appear surprising 
but is in agreement with several studies which did not detect changes in IS in the presence of 
diabetes, although other studies have described both smaller and larger IS in various animal 
models of diabetes (Miki et al., 2012). The reasons for the apparent inconsistency regarding 
the extent of myocardial IR injury in diabetes remain unclear. It is of importance that we 
investigated the efficacy of cardioprotective interventions which clearly were influenced by 
the presence of diabetes as demonstrated by the lack of cardioprotection by RIPerc in the 
diabetic animals.
In our studies we were not able to reveal whether the activity of any specific arginase isoform 
is of particular importance during myocardial IR injury since specific arginase inhibitors 
are not available. Partially this can be investigated in the future studies using arginase 2 
knockout mice. Deletion of the gene encoding for arginase 1 results in a lethal phenotype due 
to ammonia toxicity. However, endothelial cell arginase 1 conditional knockout models may 
be useful for the understanding of the arginase 1 isoform. 
We demonstrated that the reduction in arginase and ROCK activity is associated with the 
cardioprotective effect of RIPerc. Additional studies are needed to confirm whether this 
mechanism is a mediator of cardioprotection by RIPerc or not, and to clarify the lack of 
protection against myocardial IR following RIPerc in type 1 diabetes.
The results of the studies obtained in a model of type 1 diabetes cannot be translated to type 
2 diabetes a priori. Therefore further experiments are needed in order to validate the effects 
of the reported cardioprotective interventions in type 2 diabetes. 
future perspectives
Several issues remain to be solved in future. Some of them were already mentioned in the 
previous chapter discussing limitations of the studies and include disclosure of arginase 
isoforms role in myocardial IR, relevance of the observed cardioprotective effects in type 2 
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diabetes, further clarification of the mechanisms behind RIPerc. In addition, supplementation 
of the co-factor BH4 and L-arginine is of interest to be tested in diabetes. 
Novel therapeutic strategies, suggested in the thesis, should be verified in clinical trials of 
myocardial IR in patients with ST-elevation myocardial infarction. It is known that many 
previous clinical studies were unable to reproduce cardioprotective effects obtained in animal 
experiments. The present study underlines the importance of co-morbidities for effective 
cardioprotective therapy. RIPerc evoked clear reduction in IS in non-diabetic animals but 
was ineffective in a model of diabetes. Interestingly, it was shown that arginase inhibition 
reduced IS not only in healthy animals, but also in the presence of diabetes, indicating that 
this strategy may be effective also in a clinical setting of myocardial infarction in patients 
with co-morbidities. The influence of other co-morbidities and confounding factors including 
atherosclerosis, hyperlipidemia, age, smoking and medication on cardioprotective treatment 
in IR need to be carefully investigated.  Ideally, more sophisticated experimental models 
which combine several such factors in one animal would be an attractive tool to simulate 
the clinically relevant situation when myocardial infarction occurs in aged subjects with co-
morbidities and background medication. 
In addition, optimal way of drug administration should be considered in patients. Systemic iv 
administration of cardioprotective compounds may not reach the myocardium at risk unless 
collateral flow is adequate. Local intracoronary infusion in connection with reperfusion as 
employed in Study II seems promising and may be applied together with primary PCI in 
clinical studies.
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CONCLUSIONS
1. Inhibition of arginase before the onset of reperfusion reduces IS via a mechanism 
dependent on NOS activity, PKCε expression and activation of mitoKATP channels. 
2. Combined administration of L-arginine and BH4 during late ischemia and reperfusion 
reduces IS via a NOS-dependent pathway and reduced generation of superoxide.
3. Peroxynitrite and ROCK signaling pathways are involved in the upregulation of 
arginase activity during myocardial IR. Reduction in arginase activity mediated by 
reduced formation of peroxynitrite and ROCK activity is of importance for the NOS-
dependent cardioprotective effect of RIPerc.
4. Inhibition of either ROCK or arginase protects against myocardial IR injury via 
a NOS–dependent mechanism both in the presence and absence of type 1 diabetes. 
Cardioprotective effect of RIPerc and associated signaling effects on arginase, ROCK 
and NOS are abolished in type 1 diabetes.
Collectively the results demonstrate the importance of the ROCK-arginase pathway and 
availability of BH4 and L-arginine for protection against myocardial IR injury mediated by 
NO. Arginase inhibition, supplementation of BH4 and L-arginine, inhibition of ROCK and 
RIPerc are potentially effective therapeutic tools for the limitation of myocardial injury in the 
treatment of acute myocardial infarction. Diabetes is a co-morbidity that importantly limits 
the cardioprotective efficacy of molecular signaling induced by RIPerc. 
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Reduced bioavailability of nitric oxide (NO) contributes to the development of myocardial ischemia-
reperfusion (I/R) injury. Increased activity of arginase is a potential factor that reduces NO bioavailability
by competing for the substrate L-arginine. The aim of the study was to test the hypothesis that inhibition
of arginase after coronary artery occlusion protects from I/R injury and to explore possible mechanisms
behind this effect.
Male Sprague-Dawley rats subjected to 30 min of coronary artery ligation and 2 h reperfusion were
given i.v. before the reperfusion: 1) saline; 2) the arginase inhibitor N-omega-hydroxy-nor-L-arginine
(nor-NOHA); 3) nor-NOHA with the NO synthase (NOS) inhibitor NG-monomethyl-L-arginine (L-NMMA); 4)
nor-NOHA with the mitochondrial ATP-dependent K+ (mitoKATP) channel blocker 5-hydroxydecanoic
acid (5-HD); 5) nor-NOHA with the protein kinase C epsilon (PKCε) inhibitor ε-V1-2 or 6) ε-V1-2 alone.
Infarct size in the control groups was 6173% and it was reduced to 4773% (Po0.01) by nor-NOHA.
The cardioprotective effect was blocked by the NOS inhibitor L-NMMA. PKCε expression was reduced by
I/R and this reduction was attenuated by nor-NOHA. Furthermore, the PKCε inhibitor ε-V1-2 abolished
the protective effect of nor-NOHA (infarct size 6976%). In addition, the cardioprotective effect of
nor-NOHA was also abolished following blockade of the mitoKATP channel (infarct size 6271%).
Inhibition of arginase before reperfusion protects the heart from I/R injury via a NOS-dependent
pathway, increased expression of PKCε and activation of mitoKATP channels.
& 2013 Elsevier B.V. All rights reserved.1. Introduction
Current treatment of acute myocardial infarction due to cor-
onary artery occlusion is aimed at initiating reperfusion to mini-
mize myocardial damage. Early revascularization rescues the
myocardium at risk and limits infarct size, which improves the
outcome for the patient. Even though the blood supply is restored,
reperfusion itself initiates alterations that are deleterious and
enhance cellular injury, a phenomenon referred to as ischemia-
reperfusion (I/R) injury which is characterized by oxidative stress,
activation of inﬂammatory processes, and dysfunction of the
microvascular endothelium (Lemasters et al., 1996; Turer and
Hill, 2010). A key mechanism behind endothelial dysfunction is
reduction of nitric oxide (NO) bioavailability (Cohen et al., 2006)
NO produced from the substrate L-arginine by NO synthase (NOS)ll rights reserved.
ital, L3:00, KERIC, S-171 76
iakovich).is a potent vasodilator (Johnson et al., 1991), inhibits apoptosis (Li
et al., 1999) and neutrophil adherence to vascular endothelium
(Ma et al., 1993), prevents platelet aggregation (Walter and
Gambaryan, 2009) and is a scavenger of superoxide (McCall
et al., 1989). One of the intracellular pathway via which NO may
mediate protection from I/R injury is by activation of guanylate
cyclase which in turn activates protein kinases G and C which
leads to opening of the mitochondrial ATP-dependent K+ (mito-
KATP) channels (Heusch et al., 2008).
An alternative metabolic pathway for L-arginine that has
attracted recent interest is the arginase-dependent dissociation
to ornithine and urea (Durante et al., 2007, Ryoo et al., 2008).
Upregulation of arginase activity may lead to reduction of
L-arginine available for NO production and decreased endothelial
function (Vanhoutte, 2008). It has been demonstrated that argi-
nase expression and activity are increased in various pathophy-
siological cardiovascular situations including oxidative stress,
atherosclerosis and ischemia (Gonon et al., 2012; Hein et al.,
2003; Ryoo et al., 2011; Thengchaisri et al., 2006). It has recently
been demonstrated that increased myocardial arginase expression
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ing an important functional role of arginase in this condition
(Gonon et al., 2012; Jung et al., 2010). However, these previous
studies have not addressed the mechanisms underlying the
cardioprotective effects following arginase inhibition during I/R
injury. Thus, the signaling pathway remains to be clariﬁed. There-
fore, the aim of the present study was to explore the mechanism
behind the protection against I/R injury induced by arginase
inhibition in vivo. The study was designed to test the hypothesis
that arginase inhibition mediates protection against myocardial I/R
injury via increased formation of NO that results in activation of
protein kinase C epsilon (PKCε) and opening of the mitoKATP
channels.2. Materials and methods
2.1. Experimental protocol
The study was approved by the regional Ethics Committee for
laboratory animal experiments in Stockholm and conforms to the
Guide for the Care and Use of Laboratory Animals published by the
US National Institutes of Health (NIH Publication No. 85–23,
revised 1996).
Male Sprague-Dawley rats (Charles-River, Sulzfeld, Germany,
260–400 g body weight) were anesthetized with pentobarbital
(50 mg/kg) i.p. followed by an i.v. infusion of 5 mg/kg/h pento-
barbital and 30 mg/kg/h fentanyl. The absence of the hind paw
withdrawal reﬂex was used as a reference level of anesthesia.
Rectal temperature was maintained at 37.5–38.5 1C by a heated
operation table. Animals were tracheotomized and ventilated with
air by a rodent pressure controlled ventilator (50–55 strokes per
min, 9 mL/kg tidal volume). The right carotid artery was cannu-
lated and connected to a Statham blood pressure transducer for
measurement of mean arterial pressure. The heart rate was
determined from the arterial pressure curve. The left jugular vein
was cannulated for administration of drugs. The heart was
exposed via a left thoracotomy. A ligature was placed around the
left coronary artery. After completion of the surgical preparation,
the rats were allowed to stabilize for 15 min and randomized into
different groups. Ischemia was induced by tightening of the
ligature around the left coronary artery. Successful occlusion was
associated with cyanosis of the myocardial area at risk and
arrhythmias after 5–15 min of ischemia. Reperfusion was initiated
after 30 min of ischemia by removal of the snare and was
maintained for 2 h.
In an initial part of the study rats were randomized to the
following groups given: 1) saline (400 mL for infarct size determi-
nation, n¼10); 2) saline (400 mL, for determination of arginase
activity, n¼9); 3) the arginase inhibitor N-omega-hydroxy-nor-L-
arginine (nor-NOHA, 100 mg/kg, n¼8); 4) the NOS inhibitor NG-
monomethyl-L-arginine monoacetate (L-NMMA, 10 mg/kg)
followed by nor-NOHA (n¼6) or 5) the mitoKATP channel blocker
5-hydroxydecanoic acid sodium (5-HD, 10 mg/kg) followed by
nor-NOHA (n¼6).
In a second part of the study, additional rats were randomized
to vehicle (n¼13) or nor-NOHA (n¼10) as above and to the
administration of 1) the speciﬁc PKCε inhibitor ε-V1-2 (3 mg/kg)
followed by nor-NOHA (n¼6) or (2) ε-V1-2 only (3 mg/kg, n¼4).
A separate sham group (n¼5) was subjected to the same proce-
dures except that the ligature placed around the left coronary
artery was not tightened and compounds were not administered.
Saline and all substances were given i.v. as bolus injections at
15 min of ischemia except 5-HD and ε-V1-2 which were injected
i.v. at 10 min of ischemia. The dosages were based on previous
studies (Deuse et al., 2010; Gourine et al., 2005; Jung et al., 2010).L-NMMA and 5-HD have previously been shown not to affect
infarct size per se (Fryer et al., 2001; Gonon et al. 2000). Since the
effect of ε-V1-2 on infarct size per se is less documented, it was
administered to separate group of animals subjected to I/R.
2.2. Determination of infarct size and collection of myocardium
samples
Infarct size was measured as previously described (Bulhak
et al., 2007). After 2 h of reperfusion, the coronary artery was
reoccluded and 1.5 mL of 2% Evans blue solution was injected via
the left jugular vein to stain non-ischemic myocardium for
determination of the area at risk. Evans blue was not administered
to sham-operated animals. The rats were euthanized by exsangui-
nation and the heart was extracted. The right atrium, the right
ventricle and the left atrium were removed, the left ventricle was
frozen and cut into 7–9 slices perpendicular to the base-apex axis.
The third slice (counting from the apex) was weighed, the
ischemic and non-ischemic parts separated, frozen on dry ice
and kept in freezer (−80 1C) until analyzed. All other slices were
weighed, scanned from both sides for the determination of the
area at risk and put in 1% triphenyltetrazolium chloride solution
for 15 min at 37 1C to distinguish viable myocardium from necrotic.
After 24 h of incubation in 4% formaldehyde slices were scanned
again from both sides, and the extent of myocardial necrosis and
the area at risk were determined by planimetry of computer
images (Adobe Photoshop CS 2; Adobe Systems). The left ventricle
obtained from sham-operated animals was also cut into slices
which were frozen on dry ice and stored frozen (−80 1C) until
further analyses.
2.3. Arginase activity determination
Arginase activity was determined by using a colorimetric assay
previously described (Berkowitz et al., 2003). The assay measures
the urea content using α-isonitrosopropiophenone. In order to
detect arginase activity only the inhibitable fraction of urea was
used in the analysis. A lysis buffer consisting of PBS, 2 mM EDTA,
Triton X (0.1%) and protease inhibitors (Roche, Basel, Switzerland)
was freshly prepared. Lysates of homogenized myocardial tissue
was centrifuged for 15 min at 10,000 g at 4 1C. 50 μL of the
supernatant was added to 75 μL of Tris–HCl (50 mM, pH 7.5)
containing 10 mM MnCl2. The mixture was activated by heating
for 10 min at 56 1C. Each sample was then incubated at 37 1C for
1 h under three conditions with: 1) L-arginine (50 μL, 0.05 M, in
Tris–HCl pH 9.7), 2) only Tris–HCl (50 μL, pH 9.7) and 3) L-arginine
(50 μL, 0.05 m, in Tris–HCl pH 9.7) and 30 min preincubation with
the arginase inhibitor 2(S)-amino-6-boronohexanoic acid
(100 μM; Enzo Clinical Labs, Farmingdale, NY, USA). The reaction
was stopped by adding 400 μL of an acid solution (H2SO4–H3PO4–
H2O¼1:3:7). 25 μL of α-sonitrosopropiophenone (9% in ethanol)
was added to each sample, and the mixture was then heated at
100 1C for 60 min. The samples were placed in the dark for 10 min
and the urea concentration was determined at 540 nm using
spectrophotometry. The urea inhibitable fraction was then calcu-
lated and used in statistical analyses.
2.4. Immunoblotting
Frozen samples of ischemic-reperfused myocardium of vehicle
and nor-NOHA treated rats and frozen samples of myocardium
obtained from sham-operated animals were used for the evalua-
tion of PKCε by immunoblotting. Samples were homogenized in
ice cold lysis buffer containing 20 mM Tris (pH¼7.8), 137 mM
NaCl, 2.7 mM KCl, 1 mMMgCl2, 1% Triton X-100, 10% (w/v) glycerol,
10 mM NaF, 1 mM ethylenediaminetetraacetic acid, 5 mM
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phenylmethyl sulfonyl ﬂuoride, 1 mg/mL aprotinin, and 1 mM
benzamidine. The homogenates were centrifuged at 5.000 g for
20 min at 4 1C and the concentration of protein in the supernatant
in each aliquot was determined using a bicinchoninic acid protein
assay kit (Pierce Biotechnology, Rockford, IL, USA). Protein extracts
(50 mg per lane) were loaded onto a 10% SDS gel and separated by
electrophoresis. Extracts were loaded on one gel and the amount
of protein was accordingly compared pairwise. Proteins were
transferred to PVDF membranes, and Ponceau staining was used
to conﬁrm efﬁciency of transfer and to visualize protein loading.
Membranes were blocked overnight at 4 1C, and then probed with
antibodies against PKCε (BD Transduction Laboratories, Franklin
Lakes, NJ, USA). Proteins were visualized by enhanced chemilumi-
nescence with ECL advance Western blotting detection kit (Amer-
sham Biosciences, Amersham, UK) and quantiﬁed using
densitometry and Quantity One 4.5.1 software (Bio-Rad Labora-
tories, Inc., Hercules, CA, USA). Finally membranes were stripped
and immunoblotted for GAPDH (Sigma-Aldrich, St. Louis, MO,
USA) as loading control.
2.5. Chemicals
Pentobarbital was purchased from Apoteksbolaget (Stockholm,
Sweden); fentanyl from B. Braun Meslungen AG (Meslungen,
Germany); nor-NOHA from Bachem (Bubendorf, Switzerland);
L-NMMA from Alexis Biochemicals (Lausen, Switzerland); 5-HD,
Evans blue, triphenyltetrazolium chloride, Trizma base and Trizma
hydrochloride from Sigma-Aldrich (St. Louis, MO, USA); ε-V1-2
from AnaSpec, Inc (Fremont, CA, USA).
2.6. Statistical analysis
Data were analyzed using GraphPad Prism 4.00 (GraphPad
Software, Inc). Data are presented as mean7S.E.M. or mean andTable 1
Hemodynamics.
Group Parameter 15 min before ischemia Before reperf
Vehicle MAP 12973 8975
HR 464718 45376
nor-NOHA MAP 12376 8075
HR 491713 478714
L-NMMA+nor- NOHA MAP 13275 93710
HR 47978 448 715
5-HD+nor-NOHA MAP 105710 8377
HR 415719 433719
Sham operated MAP 110711 10579
HR 415723 432715
MAP: Mean arterial pressure (mmHg); HR: Heart rate (bpm). Signiﬁcant differences from
vehicle are indicated.
a Po0.05.
Table 2
Hemodynamics.
Group Parameter 15 min before ischemia Before reperfus
Vehicle MAP 13273 9575
HR 467714 45976
nor-NOHA MAP 11976 8776
HR 478713 475711
ε-V1-2+nor-NOHA MAP 11479 7977
HR 470714 451719
ε-V1-2 MAP 13173 10074
HR 476716 453716
MAP: Mean arterial pressure (mmHg); HR: Heart rate (bpm). Data are mean7S.E.M.individual measured data points. Groups were compared using
one-way ANOVA together with Newman-Keuls multiple compar-
ison post test. Unpaired t-test was used for comparisons of only
two groups. Po0.05 was considered statistically signiﬁcant.
The authors had full access to the data and take responsibility
for its integrity. All authors have read and agreed on the manu-
script as written.3. Results
3.1. Hemodynamics
Mean arterial pressure and heart rate during the experimental
procedure in all groups are presented in Tables 1 and 2.
In comparison with the control group there was no signiﬁcant
difference in mean arterial pressure or heart rate except a lower
heart rate in the group given 5-HD and nor-NOHA at 30 and
60 min of reperfusion and higher mean arterial pressure at 60 min
of reperfusion in the sham operated group.3.2. Infarct size
The two parts of the study are represented in Figs. 1 and 2,
respectively. There were no signiﬁcant differences in the area at
risk between any of the groups (Figs. 1 and 2A). In the ﬁrst part of
the study, infarct size in the control group was 6173% (Fig. 1B).
Administration of nor-NOHA signiﬁcantly reduced infarct size to
4773% (Po0.01). Administration of the NOS inhibitor L-NMMA or
the mitoKATP channel blocker 5-HD completely abolished the
cardioprotective effect of nor-NOHA (Fig. 1B). In the second part
of the study the effect of the PKCε inhibitor ε-V1-2 was investi-
gated. Administration of ε-V1-2 did not affect infarct size per se but
it abolished the cardioprotective effect of nor-NOHA (Fig. 2B).usion 30 min reperfusion 60 min reperfusion 120 min reperfusion
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7175 6374 6173
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9479 9176a 8676
419712 407714 404714
the vehicle group are indicated. Data are mean7S.E.M. Signiﬁcant differences from
ion 30 min reperfusion 60 min reperfusion 120 min reperfusion
8374 7673 7275
44178 41779 40079
7974 6974 6874
44878 43779 409712
7776 7077 6673
424727 399722 377723
9174 8679 7974
435714 407712 388711
vehicle nor-NOHA l-NMMA+nor-NOHA 5-HD+nor-NOHA
0
15
30
45
60
A
re
a 
at
 ri
sk
,  
%
 o
f L
V
vehicle nor-NOHA l-NMMA+nor-NOHA 5-HD+nor-NOHA
0
15
30
45
60
75
90
 In
fa
rc
t s
iz
e,
 %
 o
f A
A
R
Fig. 1. (A) Area at risk (AAR) expressed as % of the left ventricle (LV) and (B) infarct
size expressed as % of AAR after 30 min of ischemia and 2 h of reperfusion. The rats
were given either saline (vehicle, n¼10), the arginase inhibitor nor-NOHA (n¼8),
nor-NOHA together with the NOS inhibitor L-NMMA (n¼6), nor-NOHA together
with the selective mitoKATP channel antagonist 5-HD (n¼6). Date are presented as
mean and individual data points; *Po0.05; **Po0.01.
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Fig. 2. (A) Area at risk (AAR) expressed as % of the left ventricle (LV) and (B) infarct
size expressed as % of AAR after 30 min of ischemia and 2 h of reperfusion. The rats
were given either saline (vehicle, n¼13), the arginase inhibitor nor-NOHA (n¼10),
nor-NOHA together with the PKCε speciﬁc inhibitor ε-V1-2 (n¼6) or ε-V1-2 only
(n¼4). Data are presented as mean and individual data points; ** Po0.01.
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Fig. 3. Arginase activity in ischemic-reperfused (I/R) and in non-ischemic (NI)
myocardium of rats subjected to i.v. injection of vehicle (n¼9). Data are presented
as mean and individual data points; *Po0.05.
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Fig. 4. Quantiﬁcation and immunoblots showing the expression of protein kinase C
epsilon (PKCε) in ischemic-reperfused myocardium of rats treated with nor-NOHA,
vehicle and in myocardium of sham-operated animals. Data are presented as mean
and individual data points; **Po0.01; ***Po0.001.
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In order to evaluate the effect of I/R on arginase activity, it was
measured in ischemic and non-ischemic myocardium of animals
given saline. Arginase activity in ischemic-reperfused myocardium
was more than 2 times higher than in non-ischemic myocardium
(Fig. 3).
3.4. Myocardial protein kinase C epsilon expression
Expression of PKCε was markedly reduced in ischemic-
reperfused myocardium compared to non-ischemic myocardium
of sham-operated animals. The expression of PKCε was 7 times
higher (Po0.01) in ischemic-reperfused myocardium of the rats
treated with nor-NOHA than in those given vehicle (Fig. 4).4. Discussion and conclusions
In this study we show that arginase activity is upregulated in
the myocardium during I/R and that inhibition of arginase by
nor-NOHA after the onset of ischemia, but before reperfusion
protects from myocardial I/R injury. The protective effect is
abolished by the NOS-inhibitor L-NMMA, inhibition of PKCε and
the mitoKATP channel blocker 5-HD. Furthermore, the I/R-induced
reduction of PKCε expression was attenuated by arginase inhibi-
tion. These observations indicate that arginase inhibition protects
from reperfusion injury via a mechanism involving NOS activity,
upregulation of PKCε and activation of mitoKATP channels.
Endothelial dysfunction with diminished NO bioavailability is a
prominent feature of I/R injury (Cohen et al., 2006). Previous
studies employing pre- and postconditioning have demonstrated
that NO provides cardioprotection as a signal mediator and an
effector, both immediately following the ischemic insult and at
later time points (Sanada et al., 2011). Attenuation of NO bioavail-
ability is therefore a central mechanism behind development of I/R
injury. L-arginine is a substrate not only for NOS but also for
arginase which converts L-arginine into L-ornithine and urea
(Durante et al., 2007). Increased arginase activity may result in
reduced formation of NO due to the competition between NOS and
arginase for their common substrate L-arginine. In addition, it has
been shown that the phenomenon of NOS uncoupling, a situation
when eNOS produces superoxide instead of of NO, is provoked by
arginase upregulation and that inhibition of arginase restores the
Y. Tratsiakovich et al. / European Journal of Pharmacology 712 (2013) 16–2120nitroso-redox balance (Kim et al., 2009). The mechanism behind
this effect may be reduced availability of the eNOS substrate
L-arginine due to consumption by arginase (Romero et al., 2008).
Furthermore, reactive oxygen species, that are known to contri-
bute to the development of I/R injury, may further increase
arginase production (Pernow and Jung, 2013). Accordingly,
previous studies (Gonon et al., 2012; Jung et al., 2010) have
demonstrated that arginase inhibition results in reduction in
infarct size via a mechanism that involves production of NO.
Furthermore, the cardioprotective effect was abolished by pre-
treatment with the NOS-inhibitor L-NMMA, which does not affect
infarct size per se (Gonon et al., 2000), demonstrating that the
cardioprotective effect of arginase inhibition is dependent on NO
production. L-NMMA blocks all isoforms of NOS but neuronal NOS
has been shown not to be involved in the development of myocardial
injury (Jones et al., 2000) and inducible NOS is not inﬂuenced in the
brief protocol used (Bulhak et al., 2006). The present ﬁndings
therefore support the notion that endothelial NOS is responsible for
the cardioprotective effect of arginase inhibition. Previous studies
have suggested that the cardioprotective effect of NO includes
stimulation of cyclic guanosine monophosphate, formation of PKCε,
protein kinase G and subsequent opening of the mitoKATP channel
(Chai et al., 2011; Costa and Garlid, 2008; Sanada et al., 2001). Our
hypothesis was therefore that arginase inhibition mediates cardio-
protection via this signaling pathway induced by increased NO
production. Participation of PKCε in the cardioprotective mechanism
was tested by the administration of the PKCε speciﬁc inhibitor ε-V1-2
before the treatment with nor-NOHA. This resulted in abolition of the
cardioprotective effect of nor-NOHA. Inhibition of PKCε did not
inﬂuence infarct size per se. This latter observation can be expected
since PKCε was markedly downregulated by I/R. Moreover, we
demonstrate that the expression of PKCε was maintained in the
ischemic-reperfused myocardium after administration of nor-NOHA.
We further demonstrate that the selective mitoKATP channel blocker
5-HD completely blocked the cardioprotective effect of arginase
inhibition by nor-NOHA suggesting that its mechanism depends on
the activation of mitoKATP channels. Previous studies have estab-
lished that 5-HD does not affect infarct size per se (Fryer et al., 2001).
The involvement of mitoKATP channels is of importance due to the
central role of mitochondrial function in the regulation of I/R injury
(Heusch et al., 2008). Collectively, the data provided in the present
study indicate that arginase inhibition protects the myocardium by
increasing NO production, activation of PKCε followed by activation
of the mitoKATP channels.
In the present study nor-NOHA was administered systemically
during late ischemia (before the onset of reperfusion) as an
attempt to evaluate the feasibility to afford protection in clinically
relevant scenario. We were able to demonstrate that nor-NOHA
signiﬁcantly reduced infarct size when given systemically after the
onset of ischemia. This clinically important observation adds
signiﬁcantly to previous knowledge since it demonstrates that
the arginase inhibitor affords protection also when given systemi-
cally following the onset of ischemia. Therefore this treatment
may be effective when given in the clinical setting by i.v. admin-
istration in connection with revascularization in patients with
acute myocardial infarction.
A limitation of this study is that it is not known whether
arginase 1 or 2 is of importance during I/R injury since no arginase
isoform speciﬁc inhibitors are available. Previous data suggest that
arginase 1 is upregulated in the rat myocardium during I/R injury
which would indicate that this isoform is involved (Jung et al.,
2010). However, it is not possible to determine whether this
isoform accounts for the increase in arginase activity observed in
the present study.
In conclusion, the present study demonstrates that arginase
activity is induced by I/R injury, and that inhibition of arginaseimmediately before the onset of reperfusion reduces infarct size
via a mechanism dependent on NOS activity, PKCε expression and
activation of mitoKATP channels. The ﬁndings suggest that arginase
inhibition is a promising therapeutic target for limitation of
myocardial injury in the treatment of acute myocardial infarction.Funding
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Background: Reduced bioavailability of nitric oxide (NO) is a key factor contributing to myocardial ischemia and
reperfusion injury. The mechanism behind the reduction of NO is related to deﬁciency of the NO synthase (NOS)
substrate L-arginine and cofactor tetrahydrobiopterin (BH4) resulting in NOS uncoupling. The aim of the study
was to investigate if the combination of L-arginine and BH4 given iv or intracoronary before reperfusion protects
from reperfusion injury.
Methods: Sprague–Dawley rats and pigs were subjected to myocardial ischemia and reperfusion. Rats received
vehicle, L-arginine, BH4, L-arginine + BH4 with or without the NOS-inhibitor L-NMMA iv 5 min before reperfu-
sion. Pigs received infusion of vehicle, L-arginine, BH4 or L-arginine + BH4 into the left main coronary artery
for 30 min starting 10 min before reperfusion.
Results: Infarct sizewas signiﬁcantly smaller in the rats (50 ± 2%) and pigs (54 ± 5%) given L-arginine + BH4 in
comparisonwith the vehicle groups (rats 65 ± 3% and pigs 86 ± 5%, P b 0.05). Neither L-arginine nor BH4 alone
signiﬁcantly reduced infarct size. Administration of L-NMMA abrogated the cardioprotective effect of L-
arginine + BH4. Myocardial BH4 levels were 3.5- to 5-fold higher in pigs given L-arginine + BH4 and BH4
alone. The generation of superoxide in the ischemic-reperfused myocardium was reduced in pigs treated with
intracoronary L-arginine + BH4 versus the vehicle group (P b 0.05).
Conclusion:Administration of L-arginine + BH4 before reperfusion protects the heart from ischemia–reperfusion
injury. The cardioprotective effect is mediated via NOS-dependent pathway resulting in diminished superoxide
generation.© 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Acute ST-elevation myocardial infarction demands rapid restoration
of coronary blood ﬂow to the jeopardizedmyocardium by either prima-
ry coronary intervention or thrombolysis to limit the extent of necrosis
[1]. However, acute reperfusion of the ischemicmyocardium results in a
cascade of harmful events, referred to as reperfusion injury. Factors
contributing to the reperfusion injury include endothelial dysfunction,as supported by the Swedish
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td. All rights reserved.activation of pro-inﬂammatory cascades, intracellular calcium overload
and generation of reactive oxygen species [2,3]. Endothelium-derived
nitric oxide (NO) plays an important role as a regulator of reperfusion
injury by maintaining the vascular integrity, inhibiting inﬂammatory
processes and as a scavenger of superoxide [4]. NO production is depen-
dent on the availability of the substrate L-arginine [5] and the function of
nitric oxide synthase (NOS) [6]. During ischemia and reperfusion re-
striction of NO production is attributed to reduced availability of the
NO substrate L-arginine by increased activity of arginase [7,8] and by
reduced transport of L-arginine into the cell [9]. Earlier studies demon-
strated that administration of L-arginine or inhibition of arginase atten-
uated ischemia and reperfusion injury via an NO-mediated mechanism
[7–12].
Another reason for decreased production of NO is uncoupling of NOS
[13,14], a situation when NOS produces superoxide instead of NO. One
mechanism is lack of the essential cofactor tetrahydrobiopterin (BH4)
that leads to instability and uncoupling of NOS, reduced production of
NO and increased generation of superoxide resulting in oxidative stress,
myocardial injury and impaired contractility [15–17]. Exogenous
84 Y. Tratsiakovich et al. / International Journal of Cardiology 169 (2013) 83–88administration of the BH4 precursor sepiapterin or a synthetic analog of
BH4 restored the response to endothelium-dependent vasodilators in
pig coronary arterioles isolated from the hearts subjected to ischemia
and reperfusion [18]. Diminished NO production in the ischemic heart
ex vivo is associated with depletion of BH4 in myocardium and admin-
istration of exogenous BH4 restored NO production and improved
recovery of coronary ﬂow [19]. Intravenous pretreatment by BH4 prior
to ischemia signiﬁcantly reduced the myocardial infarct size in rats
subjected to ischemia and reperfusion [20]. Moreover, administration
of BH4 or dihydrobiopterin resulted in protection against ischemia and
reperfusion injury in the liver [21], skeletal muscle [22] and kidney
[23]. However, it is not known whether BH4 exerts cardioprotective
effects when given shortly before reperfusion. Of additional interest is
the interaction between L-arginine and BH4 in the regulation of proper
NOS function. Besides the role of BH4 for binding of L-arginine to NOS,
L-arginine has been shown to increase the levels of BH4 bound to NOS in-
dicating that also L-arginine supply is crucial for NOS coupling [24]. This
may suggest synergistic effects of L-arginine and BH4 in the setting of re-
duced bioavailability of NO production. In support of this, we have previ-
ously shown that the combination of L-arginine and BH4 protects against
forearm endothelial dysfunction induced by ischemia–reperfusion in
patients with coronary artery disease and type 2 diabetes mellitus [25].
Based on the assumption that NO production is dependent on avail-
ability of both L-arginine and BH4, we hypothesized that the combina-
tion of L-arginine and BH4 will provide protection from reperfusion
injury beyond that evoked by either compound alone. Therefore, the
aim of the present study was to investigate if administration of L-
arginine and BH4 before the onset and during reperfusion reduces
infarct size in two different species and using a protocol resembling
the clinical setting of ST-elevation myocardial infarction.
2. Methods
The study was approved by the regional Ethics Committee for laboratory animal
experiments in Stockholm and conformed to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publication No. 85-23,
revised 1996).
2.1. Experimental protocol
2.1.1. Rat
Fifty-three male Sprague–Dawley rats (260–400 g body weight, Charles River
Sulzfeld, Germany) were anesthetized with pentobarbital sodium ip (50 mg/kg) followed
by continuous iv infusion of 5 mg/kg/h pentobarbital and 30 μg/kg/h fentanyl. Rectal tem-
perature was maintained at 38 ± 0.5 °C by a heated operation table. Animals were
tracheotomized, intubated, and ventilated with air by a rodent ventilator (54 strokes/
min, 9 ml/kg tidal volume). The right carotid artery was cannulated and connected to a
Statham blood pressure transducer for the measurement of mean arterial pressure. The
heart rate was determined from the arterial pressure curve. Hemodynamic parameters
were continuously recorded on a personal computer equipped with PharmLab V4.0
(AstraZenecaR&D,Mölndal, Sweden). The left jugular veinwas cannulated for administra-
tion of drugs and Evans blue at the end of the experiment. The heart was exposed via a left
thoracotomy. A ligature was placed around the left coronary artery.
After the surgical preparation, the rats were allowed to stabilize for 15 min and ran-
domized into ﬁve groups. Ischemia was induced by tightening of the ligature around the
left coronary artery. Successful occlusion was associated with cyanosis of the myocardial
area at risk and arrhythmias after 5–15 min of ischemia. The different groups were
given: 1) saline (400 μl, n = 8); 2) BH4 (5,6,7,8-tetrahydro-L-biopterin, 10 mg/kg)
followed by L-arginine (100 mg/kg, n = 6); 3) BH4 (10 mg/kg) followed by saline
(200 μl, n = 6); 4) saline (200 μl) followed by L-arginine (100 mg/kg, n = 6); and 5)
the NOS inhibitor NG-monomethyl-L-arginine (L-NMMA, 10 mg/kg) followed by BH4
(10 mg/kg) and L-arginine (100 mg/kg, n = 6). All substances were given iv as bolus
injections at 25 min of ischemia. Reperfusion was initiated after 30 min of ischemia by
removal of the snare and was maintained for 2 h. The reperfusion was associated with
vanishing of the cyanotic color of the myocardium and arrhythmias.
2.1.2. Pig
Twenty-nine farm pigs (27–38 kg) were premedicated with tiletamine (1.5 mg/kg,
im), zolazepam (1.5 mg/kg, im) and medetomidine hydrochloride (0.06 mg/kg, im).
Anesthesia was induced by sodium pentobarbital bolus (20 mg/kg, iv) and maintained
with infusion of pentobarbital (2–4 mg/kg/h, iv) and fentanyl (0.05 mg/h, iv). The animals
received heparin 5000 IU/h, iv. The animals were intubated and mechanically ventilated
with air and oxygen. Respiratory rate and tidal volume were adjusted to keep arterialblood pH, pO2 and pCO2 within the physiological range. Rectal temperature was kept at
39.0 ± 0.2 °C by means of a heated operating table. A central venous catheter was
inserted in the right external jugular vein for drug and ﬂuid administration. Another cath-
eter was positioned in the descending aorta via the right femoral artery for determination
of blood gases and measurement of arterial pressure via a pressure transducer. Heart rate
wasdetermined from the arterial pressure curve. All variableswere continuously recorded
on personal computer equipped with PharmLab V3.0 (AstraZeneca R&D, Mölndal,
Sweden). The heart was exposed via a sternotomy. A ligature was placed around the left
anterior descending artery (LAD) at a position from which the distal third of the artery
is occluded when tightening the ligature. An ultrasonic probe (Transonic Systems Inc.,
NewYork, USA)was placed around the artery just proximal to the snare formeasurement
of coronary blood ﬂow. The ﬂow probe was connected to a Transonic 208 blood ﬂow
meter. Finally, a catheter was introduced into the right femoral artery and a guide wire
was advanced to the aortic arch under control with ﬂuoroscopy. A 5F coronary angiogra-
phy catheter was slid over the wire and placed into the left main coronary for drug
administration.
After a post-surgery stabilization period of 30 min the pigswere subjected tomyocar-
dial ischemia by tightening the ligature around the LAD. Ischemiawas induced by tighten-
ing of the ligature around LAD. The animals were randomized to receive a local infusion
into the left main stem of either: 1) saline (n = 6); 2) BH4 (0.03 mg/kg/min, n = 6); 3)
L-arginine (3.0 mg/kg/min, n = 6) or 4) the combination of L-arginine and BH4 (n = 6).
In addition the ﬁfth group received a systemic infusion of the same doses of L-arginine
and BH4 via the jugular vein (n = 5). All infusions were started at 30 min of ischemia
and were given for 30 min, i.e. until 20 min of reperfusion, at a rate of 2 ml/min. After
40 min of ischemia LAD was reperfused for 4 h by removal of the ligature.
2.2. Determination of infarct size and collection of myocardium samples
After 2 h of reperfusion in rats and 4 h of reperfusion in pigs the coronary artery was
reoccluded. An injection of 2% Evans blue solution was given iv (1.5 ml and 50 ml for rat
and pig respectively) to stain non-ischemic myocardium for determination of the area at
risk. The rats were euthanized by exsanguination and the pigs were sacriﬁced by iv injec-
tion of potassium chloride. The heart was extracted. The atria and the right ventricle were
removed. The left ventricle of the rat was frozen for 20 min (−20 °C) and cut into 7–9
slices perpendicular to the base–apex axis. The left ventricle of the pig was cut into 5–6
slices perpendicular to the heart base–apex axis without prior freezing. The third slice
(counting from the apex) was cut into the ischemic and non-ischemic parts which were
used for further analyses. All other slices were weighed, scanned from both sides for the
determination of the area at risk and put in 1% triphenyltetrazolium chloride solution
for 15 min (slices from rat) or 10 min (slices from pig) at 37 °C to distinguish viable myo-
cardium from necrotic. After 24 h of incubation in 4% formaldehyde slices from rats were
scanned again from both sides, and the extent of myocardial necrosis and the area at risk
were determined by planimetry of computer images (Adobe Photoshop CS 2, Adobe
Systems, San Jose, CA, USA). Left ventricular slices from pigs were stained in triphenyltet-
razolium chloride solution and the extent of myocardial necrosis and the area at risk were
determined by planimetry. Infarct size was expressed in percent of the area at risk.
2.3. Tetrahydrobiopterin quantiﬁcation
Myocardial BH4 levels were determined by HPLC followed by electrochemical and
ﬂuorescent detection, as previously described [26]. Tissue lysates were resuspended in
phosphate-buffered saline (50 mM), pH 7.4, containing dithioerythritol (1 mM) and
EDTA (100 μM) and subjected to three freeze–thaw cycles. After centrifugation (15 min
at 13000 rpm and 4 °C), sampleswere transferred to new, cooledmicro tubes and precip-
itated with cold phosphoric acid (1 M), trichloroacetic acid (2 M) and dithioerythritol
(1 mM). Samples were vigorously mixed and then centrifuged for 15 min at 13000 rpm
and 4 °C. Samples were injected onto an isocratic HPLC system and quantiﬁed using
sequential electrochemical (Coulochem III, ESA, Inc., North Sioux City, SD, USA). HPLC
separation was performed using a 250-mm ACE C-18 column (Hichrom, Berkshire, UK)
and a mobile phase comprised of sodium acetate (50 mM), citric acid (5 mM), EDTA
(48 μM), and dithioerythritol (160 μM, pH 5.2) (all ultrapure electrochemical HPLC
grade) at a ﬂow rate of 1.3 ml/min. Background currents of +500 μA and−50 μA were
used for the detection of BH4 on electrochemical cells E1 and E2, respectively. Quantiﬁca-
tion of BH4 was done by comparisonwith authentic external standards and normalized to
sample protein content.
2.4. Determination of superoxide production in ischemic myocardium
Left ventriclemyocardial tissue samples (size: 0.5 × 0.5 × 2.0 cm)were excised from
the area at risk following ischemia–reperfusion, and superoxide production was deter-
mined using dihydroethidium (DHE; Sigma-Aldrich, St. Louis, MO, USA) ﬂuorescence
staining [27]. In brief, the tissue blocks were embedded in optimal cutting temperature
compounds and cryosections (20 μm) were produced in cryostat Leica CM3050 S (Leica
Microsystems, Wetzlar, Germany), stained with DHE (1 μM) dissolved in phosphate buff-
er solution (pH 7.4) and incubated at 37 °C for 30 min in a dark humidiﬁed chamber. A
negative control was obtained by blocking the reaction with N-acetyl-L-cysteine
(100 mM, Sigma-Aldrich, St. Louis, MO, USA). The ﬂuorescent image was obtained using
a ﬂuorescence microscope Zeiss Axio Scope A1 (Carl Zeiss Microscopy GmbH, Jena,
Germany) with a 585 nm long-pass ﬁlter. The ﬂuorescence intensity was determined
Table 2
Hemodynamics in pigs.
Group Parameter Before
ischemia
30 min
ischemia
60 min
reperfusion
240 min
reperfusion
Vehicle MAP 98 ± 6 80 ± 14 59 ± 14 69 ± 15
HR 88 ± 6 106 ± 12 115 ± 16 150 ± 9
CF 16.5 ± 1.0 0 26.1 ± 5.8 7.3 ± 2.8
BH4 + L-arginine MAP 95 ± 7 87 ± 8 65 ± 4 67 ± 4
HR 79 ± 4 79 ± 5 99 ± 5 120 ± 7
CF 19.2 ± 2.7 0 27.8 ± 4.1 11.5 ± 3.0
BH4 MAP 96 ± 5 94 ± 6 93 ± 7 73 ± 3
HR 87 ± 12 82 ± 6 119 ± 8 121 ± 6
CF 18.6 ± 1.7 0 44.5 ± 5.0 8.5 ± 0.7
L-arginine MAP 93 ± 4 92 ± 3 81 ± 8 67 ± 4
HR 87 ± 6 119 ± 29 119 ± 6 119 ± 4
CF 19.4 ± 3.1 0 25.6 ± 3.5 8.9 ± 2.7
Systemic BH4 +
L-arginine
MAP 97 ± 3 76 ± 11 72 ± 7 64 ± 10
HR 86 ± 5 73 ± 12 101 ± 6 120 ± 7
CF 14.3 ± 0.7 0 21.5 ± 3.3 7.0 ± 1.6
MAP: mean arterial pressure; HR: heart rate; CF: coronary ﬂow. Data are mean ± SE.
There are no signiﬁcant differences between groups.
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control group.
2.5. Chemicals
Pentobarbital sodium was purchased from Apoteksbolaget (Stockholm, Sweden);
Fentanyl from B. Braun Melsungen AG (Melsungen, Germany); BH4 and L-NMMA from
Alexis Biochemicals (Lausen, Switzerland); L-arginine hydrochloride, Evans blue, triphe-
nyltetrazolium chloride, Trizma base and Trizma hydrochloride from Sigma-Aldrich
(St. Louis, MO, USA). BH4 was dissolved in distilled deoxygenated water containing
1 mM dithioerythritol as antioxidant and kept in−80 °C freezer until usage.
2.6. Statistical analysis
Data are presented as mean ± SE. Groups were compared using Kruskal–Wallis test
with Dunn's multiple comparison test. P b 0.05 was considered statistically signiﬁcant.
3. Results
Twenty-one rats were excluded from the study; 10 rats due to irre-
versible ventricular ﬁbrillation during ischemia (1 animal in the vehicle
group, 2 animals in the BH4 + L-arginine group, 1 animal in the BH4
group, 3 animals in the L-arginine group, and 3 animals in the L-
NMMA + BH4 + L-arginine group), and 11 rats due to continuously
low mean arterial pressure (exclusion criteria was mean arterial pres-
sure lower than 60 mm Hg) during the ischemic or reperfusion period
(5 animals in the vehicle group, 2 animals in the BH4 + L-arginine
group, 3 animals in the L-arginine group, and 1 animal in the L-
NMMA + BH4 + L-arginine group).
Three pigs were excluded due to irreversible ventricular ﬁbrillation
occurring during the ischemic or reperfusion periods (2 pigs random-
ized to the vehicle group and 1 pig in the L-arginine group).
3.1. Hemodynamics
There were no signiﬁcant differences in pre-ischemic hemodynamic
parameters between the groups of rats or pigs (Tables 1 and 2, respec-
tively). In rats heart rate was signiﬁcantly higher before the onset and
at the end of reperfusion in the group given L-arginine + BH4 than in
the vehicle group. There was no statistical difference in hemodynamic
parameters between the different groups of pigs during ischemia and
reperfusion.
3.2. Area at risk and infarct size
Figs. 1A and 2A depict the area at risk in the rats and pigs, respective-
ly. For each species there were no signiﬁcant differences between the
groups.
In rats infarct size was 65 ± 3% of the area at risk in the vehicle
group (Fig. 1B). Infarct sizewas not signiﬁcantly affected by administra-
tion of L-arginine (64 ± 3%) or BH4 (56 ± 3%). However, iv administra-
tion of the combination of L-arginine and BH4 resulted in a signiﬁcant
reduction of infarct size to 50 ± 2% of the area at risk (P b 0.05 vs.Table 1
Hemodynamics in rats.
Group Parameter Before
ischemia
Vehicle MAP 123 ± 6
HR 455 ± 13
BH4 + L-arginine MAP 137 ± 3
HR 510 ± 7
BH4 + vehicle MAP 131 ± 6
HR 486 ± 17
Vehicle + L-arginine MAP 122 ± 12
HR 476 ± 24
L-NMMA + BH4 + L-arginine MAP 124 ± 6
HR 461 ± 14
MAP: mean arterial pressure; HR: heart rate. Data are mean ± SE. Signiﬁcant difference fromvehicle). Administration of the NOS inhibitor L-NMMA abolished the
protective effect of L-arginine + BH4 (66 ± 4% of the area at risk).
In pigs infarct size was 86 ± 5% of the area at risk in the vehicle
group (Fig. 2B). Neither infusion of L-arginine nor BH4 alone signiﬁcantly
affected infarct size (77 ± 5% and 70 ± 5% of the area at risk, respec-
tively). Infarct size was signiﬁcantly reduced by intracoronary adminis-
tration of the combination of L-arginine and BH4 to 54 ± 5% of the area
at risk (P b 0.05 vs. vehicle). On the other hand, systemic infusion of the
same dose of L-arginine + BH4 did not inﬂuence infarct size (83 ± 6%
of the area at risk).
3.3. Myocardial tetrahydrobiopterin levels
BH4 was determined in the myocardial area at risk of pigs given
intracoronary infusion of vehicle, BH4 or the combination of BH4 and
L-arginine (Fig. 3). Myocardial BH4 levels were signiﬁcantly increased
in animals given BH4 (5.4 ± 2.6 pmol/mg) and BH4 + L-arginine
(3.5 ± 1.1 pmol/mg) in comparison with the vehicle group (0.9 ±
0.3 pmol/mg).
3.4. Superoxide production
Superoxide formation in the ischemic/reperfused myocardium
determined by DHE was signiﬁcantly lower in pigs given BH4 + L-
arginine than in vehicle treated pigs (Fig. 4). L-arginine or BH4 alone
did not signiﬁcantly affect superoxide formation.
4. Discussion
The novel ﬁnding of this study is that the combined administration
of L-arginine and BH4 during late ischemia and reperfusion reduces30 min
ischemia
30 min
reperfusion
60 min
reperfusion
120 min
reperfusion
78 ± 8 74 ± 7 70 ± 6 65 ± 6
438 ± 10 417 ± 10 408 ± 9 373 ± 7
107 ± 5 93 ± 5 91 ± 9 84 ± 6
489 ± 6 * 464 ± 16 448 ± 10 407 ± 9
87 ± 8 78 ± 8 75 ± 7 66 ± 8
472 ± 15 445 ± 21 422 ± 16 385 ± 7
100 ± 6 81 ± 4 78 ± 5 81 ± 6
469 ± 14 443 ± 15 426 ± 12 406 ± 12
91 ± 7 71 ± 4 65 ± 3 61 ± 3
442 ± 14 412 ± 13 402 ± 4 393 ± 6
vehicle is indicated (*P b 0.05).
Fig. 1. (A) Area at risk (AAR) expressed as % of the left ventricle (LV) and (B) infarct size expressed as % of AAR after 30 min of ischemia and 2 h of reperfusion. The rats were given either
saline (vehicle), BH4 with L-arginine (L-arg) or vehicle, vehicle with L-arginine, the NOS inhibitor L-NMMAwith BH4 and L-arginine. Signiﬁcant difference versus vehicle group is indicated
(*P b 0.05).
Fig. 2. (A) Area at risk (AAR) expressed as % of the left ventricle (LV) and (B) infarct size expressed as % of AAR after 40 min of ischemia and 4 h of reperfusion. The pigs were given either
saline (vehicle), BH4 with L-arginine, BH4 alone or L-arginine alone by intracoronary (ic) infusion or BH4 with L-arginine by iv infusion. Signiﬁcant difference versus vehicle group is indi-
cated (*P b 0.05).
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Fig. 3. Tetrahydrobiopterin (BH4) levels in the ischemic-reperfused myocardium of pigs
after 40 min of ischemia and 4 h of reperfusion. The pigs were given either saline (vehi-
cle), BH4 or BH4 with L-arginine by intracoronary infusion. Signiﬁcant differences from
vehicle are indicated (*P b 0.05).
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mental protocols, whereas either compound given alone failed to
induce signiﬁcant cardioprotection. The cardioprotective effect of L-
arginine + BH4 is dependent on production of NO and attenuated
superoxide generation.
Production of NO by NOS is an indisputable requirement for
cardioprotection during ischemia and reperfusion [13,14]. The present
study was designed to test the hypothesis that co-administration of
the substrate L-arginine and the co-factor for NOS (BH4) results
in protection against reperfusion injury. This was sequentially tested
in two animal models. Rats were used initially to investigate the
cardioprotective properties of BH4 and L-arginine administered system-
ically before the onset of reperfusion. Only the combination of BH4 and
L-arginine but neither the cofactor nor the substrate for NOS given alone
induced signiﬁcant reduction in infarct size. The cardioprotective effect
of BH4 + L-arginine was abolished by the NOS inhibitor L-NMMA dem-
onstrating that it was dependent on NOS activity and production of NO.
In the second part of the study a pig model was used since this species
has a cardiac anatomy and physiology that resemble the human heart
[28]. Intracoronary infusion of substances via a catheter in the left
main coronary artery could therefore be performed to resemble a clini-
cal situation in patients with ST-elevation myocardial infarction under-
going percutaneous coronary intervention. Intracoronary infusion of the
combination of BH4 and L-arginine starting before reperfusion resulted
in signiﬁcant reduction in infarct size. On the other hand, systemicFig. 4. Change in superoxide generation in the ischemic-reperfused myocardium of pigs
expressed as % change from the vehicle group after 40 min of ischemia and 4 h of reper-
fusion. The pigs were given either saline (vehicle), L-arginine, BH4 or BH4 with L-arginine
by intracoronary infusion. Signiﬁcant difference from vehicle is indicated (*P b 0.05).infusion of BH4 and L-arginine in doses that were similar to those
given by intracoronary infusion did not induce cardioprotection. This
observation suggests that the cardioprotective effect of intracoronary
infusion was mediated via a local effect in the ischemic-reperfused
myocardium. In agreementwith the data obtained in rats, intracoronary
administration of BH4 or L-arginine alone did not induce a signiﬁcant
cardioprotective effect in pigs. In contrast to previous data [10,11] our
study demonstrated that L-arginine administered proximally to the
point of occlusion did not reduce infarct size. The current data are, how-
ever, in agreement with an earlier study in pigs showing that systemic
administration of L-arginine alone did not reduce infarct size [12]. The
reason why administration of L-arginine alone might not be sufﬁcient
to signiﬁcantly reduce infarct sizemay be that it is competitivelymetab-
olized by arginase, the activity ofwhich is upregulated during ischemia–
reperfusion [7,8], and/or decreased uptake of L-arginine into the cells
[9].
Diminished availability of the NOS cofactor BH4 leads to uncoupling
of the enzyme, resulting in decreased NO production and increased
superoxide formation [15–17]. Previous studies have demonstrated
that myocardial BH4 levels are reduced during ischemia due to oxida-
tion which contributes to post-ischemic endothelial dysfunction [19]
and that systemic pretreatment of rats with BH4 prior to ischemia
results in cardioprotective effect in vivo [20]. We demonstrate that
BH4 administered alone prior to reperfusiondoes not provide signiﬁcant
reduction in infarct size neither when administered iv in rats nor by
intracoronary infusion in pigs, despite a clear increase in myocardial
BH4 levels. On the other hand, the combined administration of BH4
and L-arginine resulted in signiﬁcant infarct size reduction in both the
rat and pigmodels. This effectwas achievedwith an increase inmyocar-
dial BH4 that were comparable to that achieved with administration of
BH4 alone. The cardioprotective effect of L-arginine + BH4 was blocked
by the NOS inhibitor L-NMMA indicating that it was mediated via pro-
duction of NO. These observations suggest that the combined adminis-
tration of L-arginine and BH4 enhances NO production causing a
protection against reperfusion injury.
Several mechanistic possibilities exist that may explain the effect of
L-arginine and BH4 during reperfusion. Earlier observations suggest that
both L-arginine and BH4 are needed for coupling of NOS [29]. Further-
more, it has been shown that availability of L-arginine is crucial for
NOS coupling [24]. Relative deﬁciency of L-arginine during ischemia–
reperfusionmay be due to upregulation of arginase. Thus, the combina-
tion of BH4 and L-arginine may be needed to achieve fully coupled NOS
in the setting of ischemia–reperfusion. In support of this, we show that
superoxide formationwas signiﬁcantly reduced in pigs onlywhen given
of the combination of BH4 and L-arginine. Previously it was speculated
that the improvement of endothelial function after the treatment with
BH4 can be attributed to its antioxidant properties [30]. However, we
did not observe signiﬁcant decrease of superoxide formation or
cardioprotective effect in animals given BH4 alone. Furthermore, the
cardioprotective effect of BH4 + L-arginine was blocked by NOS inhibi-
tion. Collectively, these ﬁndings indicate that the effect of BH4 + L-
arginine was mediated enzymatically via restored NOS coupling and
NOS-dependent reduction of infarct size rather than via an antioxidative
effect of BH4. The cardioprotective effect of L-arginine and BH4 achieved
by systemic administration to rats 5 min before the onset of reperfusion
may be explained by the relatively long biological half-life of L-arginine
[31] and BH4 [32] that allows the compounds to remain in blood and
reach the area at risk at the onset of reperfusion. In addition rats have
6.1 ± 0.7% collateral ﬂow of non-ischemic ﬂowwhich is 10-fold higher
than 0.6 ± 0.2% collateral ﬂow in pigs [33]. Accordingly, since the
rat has a distinguishable collateral blood ﬂow, blood enriched with L-
arginine and BH4 may be distributed to the area at risk during coronary
artery occlusion.
Of clinical interest is the novel demonstration that it is possible to
achieve signiﬁcant reduction in infarct size by administration of phar-
macological compounds via the guide catheter in the left main coronary
88 Y. Tratsiakovich et al. / International Journal of Cardiology 169 (2013) 83–88artery during coronary artery occlusion and early reperfusion. The guide
catheter was introduced and positioned in a fashion similar to that used
in clinical practice during primary coronary interventions of patients
with ST elevation myocardial infarction. Thus, the results of the present
study suggest that it may be feasible to use the same route of adminis-
tration in the clinical situation.
This study has certain limitations that need commenting. Only one
dose of each compound was tested. The doses of L-arginine and BH4
were based on previous studies employing local infusions demonstrat-
ing either cardioprotective effect or improvement of coronary endothe-
lial function [19,34,35]. The doses used in our study are well within the
range used in these previous studies. A group given only the NOS inhib-
itor L-NMMAwas not included and therefore its effect on infarct size per
se was not determined. However, several previous studies using similar
protocols have demonstrated that NOS blockade does not affect infarct
size per se [36,37].
In conclusion, the combined administration of BH4 and L-arginine
during late ischemia and early reperfusion reduced infarct size in
two different experimental models and two different species. The
cardioprotection was mediated via a NOS-dependent pathway and
involving reduced generation of superoxide. The ﬁnding that the combi-
nation of BH4 and L-arginine provides extensive cardioprotection com-
pared to each individual compound makes it a promising therapeutic
tool for the limitation of reperfusion injury in acute myocardial
infarction. The novel route of administration of drugs through a clinical-
ly used guide catheter placed in the left main coronary artery to mimic
the clinical situation of ST-elevation myocardial infarction proved to be
amethod that induces cardioprotection in the pig. Therefore, this meth-
od could be feasible also in clinical studies aiming for intra-coronary
infusions in patients.
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Abstract
Background: Pharmacological inhibition of arginase and remote ischemic perconditioning (RIPerc) are known to protect the
heart against ischemia/reperfusion (IR) injury.
Purpose: The objective of this study was to investigate whether (1) peroxynitrite-mediated RhoA/Rho associated kinase
(ROCK) signaling pathway contributes to arginase upregulation following myocardial IR; (2) the inhibition of this pathway is
involved as a cardioprotective mechanism of remote ischemic perconditioning and (3) the influence of diabetes on these
mechanisms.
Methods: Anesthetized rats were subjected to 30 min left coronary artery ligation followed by 2 h reperfusion and included
in two protocols. In protocol 1 rats were randomized to 1) control IR, 2) RIPerc induced by bilateral femoral artery occlusion
for 15 min during myocardial ischemia, 3) RIPerc and administration of the nitric oxide synthase inhibitor NG-monomethyl-L-
arginine (L-NMMA), 4) administration of the ROCK inhibitor hydroxyfasudil or 5) the peroxynitrite decomposition catalyst
FeTPPS. In protocol 2 non-diabetic and type 1 diabetic rats were randomosed to IR or RIPerc as described above.
Results: Infarct size was significantly reduced in rats treated with FeTPPS, hydroxyfasudil and RIPerc compared to controls
(P,0.001). FeTPPS attenuated both ROCK and arginase activity (P,0.001 vs. control). Similarly, RIPerc reduced arginase and
ROCK activity, peroxynitrite formation and enhanced phospho-eNOS expression (P,0.05 vs. control). The cardioprotective
effect of RIPerc was abolished by L-NMMA. The protective effect of RIPerc and its associated changes in arginase and ROCK
activity were abolished in diabetes.
Conclusion: Arginase is activated by peroxynitrite/ROCK signaling cascade in myocardial IR. RIPerc protects against IR injury
via a mechanism involving inhibition of this pathway and enhanced eNOS activation. The beneficial effect and associated
molecular changes of RIPerc is abolished in type 1 diabetes.
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Introduction
Emerging evidence suggested a pathophysiological role of
arginase in several diseases related to endothelial dysfunction such
as atherosclerosis [1], diabetes mellitus (DM) [2] and myocardial
ischemia/reperfusion (IR) injury [3,4,5] by reducing bioavailabil-
ity of nitric oxide (NO). Arginase regulates NO bioavailability by
competing with endothelial NO synthase (eNOS) for their
common substrate L-arginine. Arginase exists in two isoforms (1
and 2) and both are widely expressed in the cardiovascular system
[6,7]. Recently, our group has demonstrated that inhibition of
arginase either prior to ischemia or reperfusion protects the heart
against IR injury through NOS- and NO-dependent mechanisms
[3,4,5]. These studies also confirmed that arginase activity is
increased within the myocardium at risk after myocardial IR. Cell
culture experiments have revealed that the expression and activity
of arginase are regulated by several factors including pro-
inflammatory cytokines, hypoxia, reactive oxygen and nitrogen
species and RhoA/Rho associated kinase (ROCK) [7,8,9].
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However, the mechanism underlying the upregulation of arginase
activity in myocardial IR still remains to be identified.
It is well known that ischemic preconditioning provides a robust
intrinsic cardioprotection in the experimental setting of myocar-
dial IR [10]. The clinical application of preconditioning is limited,
however, due to the unpredictable occurrence of myocardial
infarction. More recently, it was described that remote ischemic
perconditioning (RIPerc), defined as brief cycle(s) of IR of a remote
organ applied during sustained myocardial ischemia also reduces
myocardial infarct size [11,12]. The magnitude of cardioprotec-
tion induced by RIPerc is comparable to preconditioning [12] but
has the advantage of being feasible in the clinical setting on
patients with ST elevation myocardial infarction [13]. It is still
unclear how the protective signal translates from the remote organ
to the heart and which signaling pathways within the myocardium
that are involved as a mediator of the protection. Substantial
evidence suggests that the attenuation of the deleterious effect of
ROCK and the activation of eNOS are involved in the
cardioprotective effect of RIPerc [14,15]. Based on the link
between ROCK and arginase activity described above, we
hypothesized that the cardioprotective effect of RIPerc is
associated with down-regulation of ROCK activity and arginase
activity.
Recent studies have suggested that co-morbidities such as
diabetes attenuate the cardioprotective effect of local pre- and
postconditioning, at least in part, via attenuation of the eNOS
signaling pathway in the myocardium [16,17]. However, it is
unknown, whether the molecular signaling and the cardioprotec-
tive effect to RIPerc is affected by co-morbidities.
Therefore, the present study was design to investigate (1) the
contribution of oxidative/nitrosative stress and ROCK signaling
pathway to IR-induced arginase upregulation and (2) whether
inhibition of this pathway is involved in the cardioprotective
mechanism of RIPerc in the absence and presence of diabetes.
Materials and Methods
2.1 Ethics Statement
The study was approved by the regional Ethics Committee
(Stockholm Norra Djurfo¨rso¨ksetiska Na¨mnd, approval number
N192/12) for laboratory animal experiments in Stockholm and
conforms to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996).
2.2 Surgical procedures
The surgical interventions were similar as described previously
[3,5]. Male Sprague–Dawley rats (Charles-River, Sulzfeld, Ger-
many) were anaesthetized with sodium pentobarbital (50 mg/kg
ip, followed by 3–5 mg/kg/h iv throughout the experiment),
tracheotomized, intubated and ventilated with air by a rodent
ventilator (54 strokes/min, 9 ml/kg tidal volume). Rectal temper-
ature was maintained at 37.5–38.5uC by a heated operating table.
The right carotid artery was cannulated and connected to a
pressure transducer for measurement of mean arterial pressure
(MAP). Heart rate (HR) was determined from the arterial pressure
curve. Hemodynamic parameters were continuously recorded on
a personal computer equipped with PharmLab V5.0 (AstraZeneca
R&D, Mo¨lndal, Sweden). The left jugular vein was cannulated for
drug administration. The heart was exposed via a left thoracotomy
and a ligature was placed around the left coronary artery.
Myocardial ischemia was induced by tightening of the ligature and
successful occlusion was associated with cyanosis of the myocardial
area at risk. Reperfusion was initiated after 30 min of ischemia by
removal of the snare and was maintained for 2 h. The reperfusion
was associated with disappearance of the cyanotic color of the
myocardium. All efforts were made to minimize animals’ suffering.
2.3 Induction of type 1 diabetes mellitus
Type 1 diabetes mellitus was induced by a single iv (tail)
injection of streptozotocin (55 mg/kg, Sigma Aldrich, USA) [18].
Three days later, only rats with blood glucose levels .15.0 mM
were considered to be diabetic. The rats were given unlimited food
and water and were not supplemented with insulin or anti-
hyperglycaemic agents. Four to five weeks following streptozotocin
injection, the rats were used for IR experiments as described
above. Age matched rats served as a non-diabetic control group.
2.4 Experimental protocols
2.4.1 Protocol 1. Protocol 1 was designed to investigate
whether the peroxynitrite/ROCK signaling pathway play role in
arginase activation and whether the inhibition of this pathway is
involved in the cardioprotective mechanism of RIPerc.
After the surgical preparation rats were allowed to stabilize for
15 min and randomized into one of the following groups: (1)
control IR (CIR; no intervention during IR; n= 10), (2) RIPerc
induced by bilateral femoral artery occlusion using vessels clamps
during the last 15 min of coronary artery occlusion (n= 10), (3)
administration of the NO synthase inhibitor NG-monomethyl-L-
arginine inhibitor (L-NMMA, Alexis Biochemicals, Switzerland;
10 mg/kg, iv n= 6) just prior to RIPerc, (4) administration of the
ROCK inhibitor hydroxyfasudil (Tocris Biosience, UK; 0.5 mg/
kg, iv n= 7) 20 min prior to ischemia, or (5) administration of the
peroxynitrite decomposition catalyst 5,10,15,20-tetrakis(4-sulfona-
tophenyl)porphyrinato iron (III), chloride (FeTPPS, Calbiochem,
USA; 10 mg/kg, iv n= 6) were given 10 min prior to reperfusion.
The dosage of drugs and the length of time the femoral artery
occlusion were based on previous studies [5,12,19,20]. NOS
blockade has previously been demonstrated not to affect infarct
size per se in our laboratory [21,22,23].
2.4.2 Protocol 2. Protocol 2 aimed to assess the influence of
diabetes on the cardioprotective effect and molecular signaling
induced by RIPerc. After the surgical preparation as described
above, type 1 diabetic or age-matched non-diabetic rats were
allowed to stabilize for 15 min and randomized into four groups.
These groups were: (1) non-diabetic controls (n = 6) with no
intervention during IR (ND-CIR), (2) non-diabetic+RIPerc (ND-
RIPerc; n = 6); (3) diabetic with no intervention during myocardial
IR (DM-CIR; n= 7) and (4) diabetic+RIPerc (DM-RIPerc; n= 6).
2.5 Assessment of myocardial infarct size
Infarct size was measured as described previously [5]. Briefly,
after 2 h of reperfusion, the coronary artery was reoccluded and
1.5 ml of 2% Evans Blue was injected in the right atrium via the
left jugular vein to demarcated the area at risk (ischemic
myocardium). Then rats were euthanized rapidly by exsanguina-
tion and the heart was rapidly excised. The atria and the right
ventricle were removed. The left ventricle of hearts were frozen for
20 minutes (220uC) and cut into 5–7 slices perpendicular to the
base-apex axis. The third slice (counting from the apex) was cut
into the ischemic and non-ischemic parts and frozen at 280uC for
further analyses [5]. The remaining slices were scanned from both
sides for determination of the area at risk weighed, and put in 1%
triphenyltetrazolium chloride (TTC) for 15 min at 37uC to
distinguish the viable myocardium from the necrotic. After 24 h
of incubation in 4% formaldehyde, slices were again scanned from
both sides. Viable myocardium is stained red by TTC, whereas
necrotic myocardium appears pale yellow. The area at risk and the
The Inhibitory Effect of Remote Perconditioning on Arginase Activity
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necrotic area were determined by computerized planimetry
images (Photoshop 6.0; Adobe Systems, USA), normalized to the
weight of each slice, with the degree of necrosis expressed as the
percentage of area at risk.
2.6 Western blotting
Tissue samples from the left ventricle were extracted in lysate
buffer (containing 20 mM KCl, 1 mM MgCl2, 0.5 mM Na3VO4,
glycerol, 0.05 M NaF, 100 mM Na-pyrophosphate, Tris pH 7.8,
Triton-X (0.1%), protease inhibitor (Roche), PBS and 1 mM of
EDTA), homogenized and centrifuged for 20 min at 10000 g at
4uC. Total protein content of the extracts was quantified by using
bicinchoninic acid protein assay kit (Pierce Biotechnology, USA).
The proteins were separated on 7.5% SDS gel (10 or 40 mg/lane)
and transferred onto either polyvinylidine fluoride (Millipore,
USA) or nitrocellulose membranes (Amersham Biosciences, USA).
Membranes were blocked for 1 h at room temperature and
incubated overnight at 4uC with primary antibodies against
arginase 1 and 2 (1:1000, Sigma Prestige Antibody, USA);
phoshorylated eNOS (p-eNOS; anti-phosphorylated Ser-1177;
1:1000; BD Pharmigen, USA), total eNOS (1:1000; ABR Affinity
BioReagents, USA); 3-nitrotyrosine (3NT, 1:1000; Abcam) or
phosphorylated ezrin (p-ezrin; anti-phosphorylated Thr567,
1:1000, BD Pharmingen, USA). IRDye 800-conjugated goat
anti-mouse IgG (1:12000, LI-COR), IRDye 800-conjugated goat
anti-rabbit IgG (1:12000, LI-COR) and IRDye 680 (1:10000) used
as secondary antibody and bands visualized using infrared
fluorescence scanner (IR-Odyssey, LI-COR Biosciences, USA).
Equal loading was confirmed by expression of GAPDH (1:5000,
Sigma Aldrich, USA) or, for 3NT, staining with Coomassie
brilliant blue. Band densities were analyzed with Image Studio Lit
Version 3.1 (LI-COR Biosciences, USA) and expressed percent of
controls.
2.7 Determination of ROCK and arginase activity
Activity of ROCK was determined similar to described
previously [14]. Briefly, left ventricular tissue samples were
prepeared as described above. To evaluate Rho-kinase activity,
the extent of phosphorylation of ezrin (Thr567) was determined by
Western blotting.
Arginase activity was determined by using a modified color-
imetric assay previously described [24]. The assay measures the
urea content using a-isonitrosopropiophenone. Tissue samples
from the area at risk and non-risk of the left ventricle were
homogenized and centrifuged (see above), 50 ml of the supernatant
was added to 75 ml of Tris-HCl (50 mM, pH 7.5) containing
10 mM MnCl2. The mixture was activated by heating for 10 min
at 56uC. Each sample was then incubated at 37uC for 1 h with: (1)
L-arginine (50 ml, 0.05 M, in Tris-HCl pH 9.7) and (2) L-arginine
with 30 min preincubation with the arginase inhibitor 2 (S)-amino-
6-boronohexanoic acid (100 mM; Enzo Clinical Labs, Farming-
dale, NY, USA). The reaction was stopped by adding 400 ml of an
acid solution (H2SO4–H3PO4–H2O=1:3:7). 25 ml of a-isonitro-
sopropiophenone (9% in ethanol), and the mixture was then
heated at 100uC for 60 min. Arginase activity was calculated as
urea (mmol/mg protein/min) production and expressed in percent
of control.
2.8 Statistical analysis
Data are presented as mean 6 SEM. For multiple comparisons
between several groups one-way ANOVA followed by Bonferroni
post hoc test was used (Prism 5 software, GraphPad Inc., USA).
Mann Whitney U-test was used for comparisons of only two
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groups where appropriate. The P-value,0.05 was considered to
be significant.
Results
3.1 Hemodynamics
Hemodynamic parameters of animals included in protocol 1
and 2 are presented in Table 1 and 2. There was no significant
difference in MAP or HR between the groups in protocol 1
(Table 1). In protocol 2, baseline HR was significantly lower in
rats with diabetes in comparison with the non-diabetic controls
(Table 2).
3.2 Results of protocol 1
3.2.1 Effect of peroxynitrite and ROCK on arginase and
ROCK activity in IR. The effect of peroxynitrite and ROCK
activity were determined by the peroxynitrite decomposition
catalyst FeTPPS and the ROCK inhibitor hydroxyfasudil,
respectively. There was no difference in the area at risk between
groups (Fig. 1A). Infarct size was significantly reduced by both
FeTPPS and hydroxyfasudil (5164% and 4963% of the area at
risk, respectively) in comparison with the CIR group (6962%,
Fig. 1C). FeTPPS and hydroxyfasudil markedly suppressed
arginase activity in tissue samples taken from the area at risk of
the left ventricle following IR (Fig. 2A, P,0.001 vs. CIR) without
affecting expressions of either arginase 1 or 2 protein (Fig. 2B and
Table 2. Hemodynamic changes in Protocol 2.
GROUP Parameters Baseline Ischemia 30 min Reperfusion 30 min Reperfusion 60 min Reperfusion 120 min
ND- CIR MABP 9262 7766 8566 8266 7762
HR 422611 39168 38469 38567 37966
ND- RIPerc MABP 9863 8267 8263 8565 7563
HR 41469 388610 387615 38269 374611
DM- CIR MAB 9768 8262 8262 7766 7265
HR 36366* 33467* 33666* 32867* 32062*
DM- RIPerc MABP 9764 8064 8363 7965 7762
HR 36064* 34066* 347613* 34568* 328610*
Values are mean 6 SEM; n = 6–7. Abbreviations: MABP (mm Hg), mean arterial blood pressure; HR (beats/min), heart rate; ND-CIR, non-diabetic control ischemia/
reperfusion; ND-RIPerc, non-diabeic remote ischemic perconditioning; DM-CIR: diabetes mellitus control ischemia/reperfusion; DM-RIPerc, diabetes mellitus remote
perconditioning.
*P,0.05 vs. ND-CIR.
doi:10.1371/journal.pone.0104731.t002
Figure 1. Myocardial area at risk and infarct size. Area at risk (A and B) expressed as % of left ventricle and infarct size (C and D) expressed as %
of the area at risk following 30 min ischemia and 2 hrs reperfusion in rats included in protocol 1 (A and C) and in non-diabetic and diabetic rats
included in protocol 2 (B and D). Values are means6 SEM; n = 6–10. **P,0.01, ***P,0.001 vs. CIR; ###P,0.001 vs. RIPerc and {{{P,0.001 vs. ND-CIR.
doi:10.1371/journal.pone.0104731.g001
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2C). By contrast, arginase activity in non-ischemic myocardium
was unaffected by either FeTTPS or hydroxyfasudil (data not
shown). In addition, FeTPPS suppressed the phosphorylated form
of ezrin as a marker of ROCK activity in compared to controls
following IR by a magnitude similar to that induced by the ROCK
inhibitor (Fig. 3A, P,0.001).
3.2.2 Effect of RIPerc on infarct size and ROCK–arginase
activity. RIPerc reduced infarct size by a magnitude compara-
ble to that induced by FeTTPS and hydroxyfasudil (Fig. 1C). In
addition, RIPerc markedly reduced arginase activity (Fig. 2A) and
ROCK activity (Fig. 3A). These effects of RIPerc were completely
abolished by administration of L-NMMA (Figs. 1C, 2A and 3A).
3.2.3 Effect of RIPerc on eNOS phoshorylation and
peroxynitrite formation. Total and phosphorylated
(Ser1177) eNOS was determined in left ventricle tissue samples
taken from the area at risk from CIR and RIPerc groups. RIPerc
enhanced phoshorylation of eNOS at Ser1177 following IR
(Fig. 4A). In addition, the level of 3NT, a marker of peroxynitrite
formation, was markedly attenuated by RIPerc (Fig. 4C).
3.3 Results of protocol 2
3.3.1 Characteristics of type 1 diabetes. Blood glucose
level was 27.361.0 mmol/l four weeks after the administration of
streptozotocin compared to 4.960.2 mmol/l in the control group
(P,0.001). Body weight was significantly lower in the diabetic
group (291612 g) than in the control group (39469 g, P,0.001).
3.3.2 Infarct size in protocol 2. Infarct size was similar in
non-diabetic and diabetic animals subjected to IR (Fig. 1D). As in
animals included in protocol 1, RIPerc resulted in a significant
reduction of infarct size in the non-diabetic group (Fig. 1D). In
contrast, RIPerc failed to reduce infarct size in rats with type 1
diabetes in comparison with controls (6862% of area at risk in
DM-CIR: vs. 6362% in DM-RIPerc; Fig. 1D).
3.3.3 Arginase expression and ROCK–arginase activity
following IR in diabetes. Arginase activity in non-ischemic
myocardium was increased by 48611% (P,0.05) in rats with type
1 diabetes compared to non-diabetic controls. Furthermore,
arginase activity was increased in myocardium from the area at
risk (ischemic) of rats with diabetes (by 70620%) and in non-
diabetic control rats (by 87611%), (P,0.01) in comparison with
non-ischemic myocardium. In tissue samples from the area at risk
of the left ventricle arginase activity was significantly reduced by
RIPerc in the non-diabetic control rats (Fig. 5A). By contrast,
RIPerc did not affect arginase activity rats with diabetes (Fig. 5B).
The expressions of arginase 1 or 2 protein were unaffected by
RIPerc (Fig. 5C–F). Moreover, in contrast to the marked changes
observed in non-diabetic rats, RIPerc failed to reduce ROCK
activity or to increase the expression of phosphorylated eNOS at
Ser1177 in rats with diabetes (Figs. 3 and 4).
Discussion
The main findings of the current study are that (1) upregulation
of arginase activity by IR is mediated by peroxynitrite and ROCK
activity in the myocardium, (2) RIPerc induced by bilateral
femoral artery occlusion during sustained myocardial ischemia
protects the heart against IR injury via a mechanism involving
attenuated peroxynitrite formation and ROCK signaling, (3) the
inhibition of this pathway results in downstream attenuation of
arginase and increased NOS activity, and (4) the cardioprotective
effect as well as the associated down-regulation of ROCK and
Figure 2. Arginase activity and protein expression in protocol 1. (A) Administration of the peroxynitrite decomposition catalyst FeTPPS, the
ROCK inhibitor hydroxyfasudil (H.fasudil), remote ischemic preconditioning (RIPerc) and RIPerc+L-NMMA on arginase activity following ischemia/
reperfusion. (B and C) Arginase 1 and 2 protein expression is depicted as representative blots. Values are means 6 SEM n= 5–10. ***P,0.001 vs. CIR;
###P,0.001 vs. RIPerc.
doi:10.1371/journal.pone.0104731.g002
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arginase activity induced by RIPerc is abolished in a model of type
1 diabetes.
There is strong evidence that myocardial IR-injury is critically
dependent on enhanced arginase activity resulting in reduced NO
production and bioavailability [3,4,5]. In addition, available
evidence suggests that arginase activity is significantly increased
in the myocardium at risk already within 20 min after the onset of
reperfusion [25]. Although the protective effect of arginase
inhibition under IR has been confirmed, the exact mechanism
regarding the upregulation of arginase activity in the myocardium
is still unknown. Data obtained in cultured endothelial cells suggest
that peroxynitrite is an upstream mediator of ROCK and arginase
activation [8,9]. Since both peroxynitrite and ROCK activity are
increased upon reperfusion and contribute to myocardial IR injury
[26,27], we hypothesized that peroxynitrite and ROCK are
possible upstream activators of arginase in the myocardium during
IR in vivo. We demonstrate that administration of the peroxyni-
trite decomposition catalyst FeTPPS prior to the onset of
reperfusion significantly reduced both ROCK and arginase
activity, indicating that peroxynitrite is an activator of ROCK
and arginase during myocardial IR. Furthermore, inhibition of
ROCK suppressed arginase activity during myocardial IR. These
findings are agreement with previous data from cell culture studies
[8] and suggest that peroxynitrite-induced ROCK signaling
stimulates arginase activity in the myocardium during IR.
Although FeTPPS and hydroxyfasudil attenuated arginase activ-
ity, expression of arginase 1 and 2 protein was unaffected. In
accordance with previous results [4] this indicates that alterations
in myocardial arginase activity are not critically dependent on
changes in arginase protein levels.
Next we investigated whether the peroxynitrite-ROCK-argi-
nase-NO pathway is involved in the cardioprotective effect
mediated by RIPerc. The reduction in infarct size induced by
RIPerc was associated with a down-regulation of ROCK activity,
which is in line with a previous observation [14]. In addition, we
demonstrate that RIPerc reduced the 3NT-levels reflecting
attenuated peroxynitrite formation. Based on the finding that the
peroxynitrite-ROCK pathway activate arginase in IR, we
hypothesized that arginase may be down-regulated by RIPerc.
Accordingly, the endogenous cadioprotective mechanism triggered
by RIPerc reduces myocardial arginase activity following IR.
Since both inhibition of ROCK and arginase is known to result in
increased eNOS activity [3,28,29] and enhanced eNOS substrate
availability, we explored the effect of RIPerc following NOS
inhibition and its effect on eNOS phosphorylation. In accordance
with previous studies demonstrating the protective effect of eNOS
and NO against myocardial IR injury [30,31], we found that
RIPerc increased eNOS phosphorylation at Ser1177. Further-
more, the cardioprotective effect of RIPerc was completely
abolished by the NOS inhibitor L-NMMA, confirming involve-
ment of NOS. Since previous studies have shown that arginase
inhibition protects from myocardial IR injury by a mechanism
dependent on NOS activity and bioavailability of NO [3,4,5], it is
tempting to speculate that down regulation of arginase is involved
in the cardioprotective effect mediated by RIPerc. This needs to
be established in future studies, however.
In this study, we demonstrate that RIPerc failed to induce
cardioprotection in a rat model of type 1 diabetes. It is well
Figure 3. ROCK activity expressed as a phosphorylation of
ezrin following ischemia/reperfusion. (A) Effect of the peroxyni-
trite decomposition catalyst FeTPPS, the ROCK inhibitor hydroxyfasudil
(H.fasudil), remote ischemic preconditioning (RIPerc) and RIPerc+the
NOS inhibitor L-NMMA in protocol 1. (B and C) Effect of RIPerC in non-
diabetic and diabetic rats of protocol 2. Values are means6 SEM; n = 5–
7. ***P,0.001 vs. CIR; ###P,0.001 vs. RIPerc and {{P,0.01 vs. ND-CIR.
doi:10.1371/journal.pone.0104731.g003
Figure 4. The effect of RIPerc on eNOS expression and
peroxynitrite formation. (A and C) Effect of remote ischemic
perconditioning (RIPerc) on phosphorylated of eNOS at Ser1177 (p-
eNOS), total eNOS and nitrotyrosine (3NT) in protocol 1. (B) Effect of
RIPerc on NOS expression in non-diabetic and diabetic rats of protocol
2. Values are means 6 SEM; n = 5–8. *P,0.05 vs. CIR.
doi:10.1371/journal.pone.0104731.g004
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established that the sensitivity of the diabetic heart to local pre-
and postconditioning is impaired [32], but this is to the best of our
knowledge the first demonstration that the cardioprotective effect
of remote ischemic perconditioning is lost in diabetes. This may, at
least in part, be associated with the dysregulation of signaling
pathway activating eNOS [16,32]. In accordance, we found that
myocardial eNOS (Ser1177) phosphorylation was increased in
non-diabetic rats but unaffected by RIPerc in diabetic rats.
Previous studies showed that increased arginase and ROCK
activity are involved in diabetes-induced vascular dysfunction via
mechanisms, at least in part, associated with reduction in NO
bioavailability [2,33]. It has further been demonstrated that the
Rho/ROCK signaling pathway is enhanced in the diabetic
myocardium [34]. In the present study we show that myocardial
arginase activity is increased rats with type 1 diabetes compared to
non-diabetic controls. Interestingly, both arginase and ROCK
activity was unchanged by RIPerc in the diabetic group, which is
in sharp contrast to the down-regulation of arginase and ROCK
activity by of RIPerc in non-diabetic rats. It remains to be
established whether diabetes-induced upregulation of ROCK and
arginase activity contribute to failure of RIPerc to induce
cardioprotection in type 1 diabetes.
There are some limitations with the present study that deserve
consideration. First, L-NMMA completely abolished the cardio-
protective effect of RIPerc. We did not include a group receiving
L-NMMA alone since it previously has been shown that L-
NMMA and other NOS inhibitors do not influence IR injury per
se [21,22,23]. Second, the current study demonstrates that
reduced arginase and ROCK activity is associated with the
cardioprotective effect of RIPerc, but the data do not provide
evidence regarding a causative effect. Additional studies are
needed to confirm whether this mechanism is a mediator of
cardioprotection by RIPerc. Third, although our data demonstrate
loss of cardioprotection induced by RIPerc in a model of type 1
diabetes, further studies are needed to establish whether similar
effect are obtained in other models of diabetes including type 2
diabetes. Fourth, further studies are needed to clarify if the loss of
the cardioprotective effect of RIPerc in type 1 in diabetes is due to
impairment of signal transduction from the remote organ to the
heart and/or impairment of protective signaling pathways in heart
and their relation to arginase and ROCK activity.
In conclusion, the present study demonstrates that peroxynitrite
and ROCK signaling pathways are involved in the upregulation of
arginase activity during myocardial IR. In addition, we propose
that reduction in arginase activity mediated by reduced formation
of peroxynitrite and ROCK activity is of importance for the NOS-
dependent cardioprotective effect of RIPerc. Importantly, our
study also demonstrates that the cardioprotective effect and the
associated signaling effects on arginase, ROCK and NOS by
RIPerc are abolished in a model of type 1 diabetes.
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Abstract
Aim: 
RhoA/Rho associated kinase (ROCK) and arginase are implicated in vascular complications 
in diabetes. This study investigated whether ROCK and arginase inhibition protect from 
myocardial ischemia-reperfusion injury in type 1 diabetes and the mechanisms behind these 
effects.
Methods: 
Rats with streptozotocin-induced type 1 diabetes and non-diabetic rats were subjected to 30 
min myocardial ischemia and 2 h reperfusion after being randomized to treatment with: 1) 
saline, 2) ROCK inhibitor hydroxyfasudil, 3) NO synthase (NOS) inhibitor NG-monomethyl-
L-arginine monoacetate (L-NMMA) followed by hydroxyfasudil, 4) arginase inhibitor 
N-omega-hydroxy-nor-L-arginine (nor-NOHA), 5) L-NMMA followed by nor-NOHA or 6) 
L-NMMA given iv before ischemia.
 
Results: 
Myocardial arginase activity, arginase 2 expression and ROCK activity were increased in type 
1 diabetes (P<0.05). ROCK inhibition and arginase inhibition significantly reduced infarct size 
in diabetic and non-diabetic rats (P<0.001). The cardioprotective effects of hydroxyfasudil 
and nor-NOHA in diabetes were abolished by NOS inhibition. ROCK inhibition attenuated 
myocardial arginase activity in diabetic rats via a NOS-dependent mechanism.
Conclusions: 
Inhibition of either ROCK or arginase protect from ischemia-reperfusion injury in rats 
with type 1 diabetes via a NOS-dependent pathway. These results suggest that inhibition of 
ROCK and arginase constitutes a potential therapeutic strategy to protect the diabetic heart 
against ischemia-reperfusion injury.
Keywords: Diabetes, Rho kinase, arginase, ischemia-reperfusion.
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Introduction
It is well known that nitric oxide (NO) formed by endothelial nitric oxide synthase (NOS) 
plays a pivotal role in cardiovascular regulation.1 Emerging evidence suggests that a decrease 
in NO bioavailability is a key factor behind cardiovascular disease including ischemia-
reperfusion (IR) injury associated with myocardial infarction2 and vascular complication in 
diabetes3, 4. Although the signaling events leading to reduction in NO bioavailability remain 
to be fully clarified, recent data suggest that upregulation of RhoA/Rho associated kinase 
(ROCK)5 and arginase6 are involved. Growing evidence suggests a pivotal role for ROCK in 
the pathophysiology of cardiovascular diseases associated with endothelial dysfunction and 
inflammation.5 It has also been suggested that increased ROCK signaling events contribute 
to myocardial IR injury.7 Interestingly, arginase which converts arginine to citrulline is 
also activated during myocardial IR which results in reduced NO production due to a shift 
in arginine metabolism from NOS to arginase.8-11 Two isoforms of arginase (1 and 2) are 
represented in the cardiovascular system,6, 12 and inhibition of this enzyme protects the 
heart against IR injury through NO-dependent mechanisms9-11. The activity and expression 
of arginase are stimulated by reactive oxygen species and proinflammatory cytokines via 
the ROCK pathway.6, 13, 14 We recently demonstrated that pharmacological inhibition of the 
ROCK pathway significantly reduced infarct size and arginase activity in the ischemic-
reperfused myocardium15, indicating an important interaction between ROCK and arginase 
in the setting of myocardial IR.
 
Both the ROCK and arginase pathways are activated in diabetes mellitus – a disease 
associated with cardiovascular complications and poor outcome following acute myocardial 
infarction.4, 16-18 Thus, ROCK and arginase activities are enhanced in the vasculature and have 
been proposed to be involved in the development of vascular dysfunction in diabetes.19-23 
Considering that activated ROCK mediates up-regulation of arginase that contributes to 
impaired vascular function in diabetes24, there seems to be an intriguing signaling pathway 
including ROCK-mediated activation of arginase leading to reduction in NO bioavailability 
and cardiovascular complications in diabetes. Moreover, it has been shown that the diabetic 
heart is more resistant to pharmacological and non-pharmacological (classical pre- and 
postconditioning) treatments aiming at reduction of IR injury.25 In light of our recent 
observation showing that remote ischemic perconditioning was ineffective in type 1 diabetic 
rats15, there is a need for identification of specific pharmacological strategies that protect 
from IR injury in diabetes.
Based on these observations, the aim of the present study was to investigate whether inhibition 
of ROCK and arginase protect from IR injury in a rat model of type 1 diabetes and to identify 
the mechanisms behind these effects. We hypothesized that targeting ROCK has beneficial 
effects in the setting of myocardial IR in diabetes via a mechanism involving downregulation 
of arginase activity and increased NO bioavailability. 
Methods
The study was approved by the regional Ethics Committee for laboratory animal experiments 
in Stockholm and conforms to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Induction of type 1 diabetes mellitus
Male Sprague-Dawley rats (Charles-River, Sulzfeld, Germany) of age 5-6 weeks were used 
in the study. Type 1 diabetes mellitus was induced by a single injection of streptozotocin 
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(STZ, 55 mg/kg) dissolved in sterile Dulbecco’s phosphate buffered saline (DPBS) in the 
tail vein under anesthesia with isoflurane mixed with oxygen.15 Only rats with blood glucose 
levels >15 mmol L-1 72 h after the STZ injection were considered to be diabetic and were 
included in the study. Healthy age matched rats received an iv injection of vehicle (DPBS) 
and served as a non-diabetic control group. Blood glucose concentration was measured 
weekly by FreeStyle Lite blood glucose monitoring system (Abbot Diabetes Care Inc., CA, 
USA). The rats were used for further experiments four to five weeks after the injection of 
STZ or vehicle during which time they were given food and water ad libitum.
Experimental protocol
Rats were anesthetized with pentobarbital (50 mg kg-1) ip followed by an iv infusion of 5 
mg kg-1 h-1 pentobarbital. Rectal temperature was maintained at 37.5-38.5°C by a heated 
operation table. Animals were tracheotomized and ventilated with air by a rodent pressure 
controlled ventilator (50-55 strokes min-1, 9 ml kg-1 tidal volume). The right carotid artery 
was cannulated and the catheter connected to a Statham blood pressure transducer for 
measurement of mean arterial pressure. Heart rate was determined from the arterial pressure 
curve. Hemodynamic parameters were continuously recorded on a personal computer 
equipped with PharmLab V5.0 (AstraZeneca R&D, Mölndal, Sweden). The left jugular vein 
was cannulated for administration of drugs. The heart was exposed via a left thoracotomy. 
A ligature was placed around the left coronary artery. After completion of the surgical 
preparation, the rats were allowed to stabilize for at least 15 min before being randomized 
into different groups (see below). Ischemia was induced by tightening of the ligature around 
the left coronary artery. Successful occlusion was associated with cyanosis of the myocardial 
area at risk. Reperfusion was initiated after 30 min of ischemia by removal of the snare and 
was maintained for 2 h. The reperfusion was associated with disappearance of the cyanotic 
color of the myocardium.
In one part of the study aimed at investigating the role of ROCK, rats with and without 
diabetes were randomized to the following treatments given iv 15 min prior to coronary 
artery ligation: 1) saline (n=5, non-diabetic rats; n=5, diabetic rats); 2) ROCK inhibitor 
hydroxyfasudil (0.5 mg kg-1; n=5, non-diabetic rats; n=5, diabetic rats); 3) NOS inhibitor NG-
monomethyl-L-arginine monoacetate (L-NMMA, 10 mg kg-1) followed by hydroxyfasudil 
(n=5, diabetic rats) or 4) L-NMMA only (10 mg kg-1, n=4, diabetic rats). 
In an additional part of the study aimed at investigating the role of arginase, separate rats with 
and without diabetes were randomized to the following treatments given iv 15 min prior to 
coronary artery ligation: 1) saline (n=7, non-diabetic rats; n=14, diabetic rats); 2) arginase 
inhibitor N-omega-hydroxy-nor-L-arginine (nor-NOHA, 100 mg kg-1; n=8, non-diabetic rats; 
n=11, diabetic rats); 3) L-NMMA (10 mg kg-1) followed by nor-NOHA (100 mg kg-1, n=7, 
diabetic rats).
 
The doses were based on previous studies. L-NMMA has previously been shown not to affect 
infarct size per se26 and to abolish the cardioprotective effects of ROCK inhibition15 and 
arginase inhibition9 in animals without diabetes using a similar protocol. These groups were 
therefore not repeated in this study.
Determination of infarct size and collection of myocardial samples
Infarct size was measured as previously described.11 After 2 h of reperfusion, the coronary 
artery was reoccluded and 1.5 ml of 2% Evans blue solution was injected into the left 
jugular vein to stain non-ischemic myocardium for the determination of the area at risk. 
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The rats were euthanized by exsanguination and the heart was extracted. The right atrium, 
the right ventricle and the left atrium were removed, the remaining left ventricle was frozen 
and cut into 7-9 slices perpendicular to the base-apex axis. The third slice (counting from the 
apex) was weighed, and the ischemic and non-ischemic parts separated, frozen on dry ice 
and stored at -80°C until analyzed. All other slices were weighed, scanned from both sides 
for the determination of the area at risk and put in 1% triphenyltetrazolium chloride solution 
for 15 min at 37°C to distinguish viable myocardium from necrotic. After 24 h of incubation 
in 4% formaldehyde slices were scanned again from both sides, and the extent of myocardial 
necrosis and the area at risk were determined by planimetry of computer images (Adobe 
Photoshop 6.0, Adobe Photoshop CS 2; Adobe Systems, CA, USA). 
Determination of arginase and ROCK activity
Arginase activity was determined by using a colorimetric assay previously described.15 
The assay measures the urea production using α-isonitrosopropiophenone. Following 
homogenization and centrifugation of tissue samples, 50 μl of the supernatant was added to 
75 μl of Tris-HCl (50 mmol L-1, pH 7.5) containing 10 mmol L-1 MnCl2. The mixture was 
activated by heating for 10 min at 56°C. Each sample was then incubated at 37°C for 1 h with 
L-arginine (50 μL, 0.5 M, in Tris-HCl pH 9.7). The reaction was stopped by adding 400 μl 
of an acid solution (H2SO4–H3PO4–H2O=1:3:7). 25 µL of α-isonitrosopropiophenone (9% in 
ethanol) was added to the mixture and then heated at 100°C for 60 min. Arginase activity was 
calculated as µmol urea/mg protein/h and expressed as fold change from the control group. 
Activity of ROCK was determined as described previously by analyzing the extent of 
phosphorylation of ezrin (Thr567) by immunoblotting.15
Immunoblotting
Left ventricular tissue samples were extracted in ice-cold RIPA buffer. Total protein 
content of the extracts was quantified by using bicinchoninic acid protein assay kit (Pierce 
Biotechnology, Rockford, IL, USA). The proteins were separated on a 7.5% SDS gel (40 
µg lane-1) and transferred onto nitrocellulose membranes (Amersham Biosciences, USA). 
Membranes were blocked for 1 h at room temperature and incubated overnight at 4°C with 
primary antibodies against arginase 1 and arginase 2 (1:1000, Sigma Aldrich, USA) or 
phosphorylated ezrin (p-ezrin; anti-phosphorylated Thr567, 1:1000, BD Pharmingen, USA). 
IRDye 800-conjugated goat anti-rabbit IgG (1:15000, LI-COR Biosciences, Lincoln, NE, 
USA) was used as secondary antibody and bands were visualized using infrared fluorescence 
scanner (IR-Odyssey, LI-COR Biosciences, Lincoln, NE, USA). Equal loading was confirmed 
by expression of GAPDH (1:5000, Sigma Aldrich). Band densities were analyzed with Image 
Studio Lite Version 3.1 (LI-COR Biosciences, Lincoln, NE, USA).
Chemicals
Pentobarbital was purchased from Apoteksbolaget (Stockholm, Sweden); hydroxyfasudil 
from Tocris Bioscience (Bristol, UK); nor-NOHA from Bachem (Bubendorf, Switzerland); 
L-NMMA from Alexis Biochemicals (Lausen, Switzerland); STZ, Evans blue, 
triphenyltetrazolium chloride, Trizma base and Trizma hydrochloride from Sigma-Aldrich 
(St. Louis, MO, USA).
Statistical analysis
Data are presented as mean±SEM. Repeated-measures two-way ANOVA with Bonferroni 
post-hoc test was used for multiple comparisons of hemodynamic parameters. One-
way ANOVA followed by Bonferroni post hoc test was used for comparisons of protein 
expression, enzyme activity and infarct size. Mann Whitney U-test was used for comparisons 
of two groups. A P-value <0.05 was considered to be significant. All analyses were performed 
using Prism™ 5 software (GraphPad Inc., San Diego, CA, USA).
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Results
Matching of diabetic and non-diabetic rats
In the first part of the study blood glucose was 28.8±0.4 mmol L-1 four weeks after the 
administration of STZ compared to 4.5±0.1 mmol L-1 in the control group (P<0.001). Body 
weight was significantly lower in the diabetic group (278±8 g) than in the control group 
(386±6 g, P<0.001).
 
In the second part of the study blood glucose was 26.6±0.4 mmol L-1  four weeks after the 
administration of STZ compared to 4.7±0.1 mmol L-1 in the control group (P<0.001). Body 
weight was significantly lower in the diabetic group (295±7 g) than in the control group 
(408±6 g, P<0.001). 
There were no differences in blood glucose or body weight between the groups within the 
non-diabetic or diabetic rats, respectively.
Hemodynamics in rats subjected to myocardial IR
Hemodynamic parameters of the rats included in the first and the second part of the study are 
presented in Table 1 and 2, respectively. In comparison with the non-diabetic animals, heart 
rate was significantly lower in rats with type 1 diabetes (P<0.05). There were no significant 
differences in heart rate or mean arterial pressure among non-diabetic or diabetic rats between 
the two parts of the study.
Infarct size
There were no significant differences in the area at risk between any of the groups (Figure 1A 
and 2A). Infarct size was comparable in the two parts of the study and it did not differ between 
diabetic control rats and non-diabetic controls (Figure 1B and 2B). The ROCK inhibitor 
hydroxyfasudil significantly reduced infarct size by comparable magnitudes in diabetic and 
non-diabetic rats from 66±2% and 66±2% to 48±4% and 46±2%, respectively (P<0.001, 
Figure 1B). Administration of the NOS inhibitor L-NMMA did not influence infarct size per 
se but abolished the cardioprotective effect of ROCK inhibition in diabetic rats (Figure 1B).
Administration of nor-NOHA significantly reduced infarct size both in diabetic and non-
diabetic rats from 67±3% and 68±3% to 51±3% and 45±4% respectively (P<0.001, Figure 
2B). The NOS inhibitor L-NMMA abolished the cardioprotective effect of nor-NOHA in 
diabetic rats (Figure 2B).
Effect of diabetes on ROCK activity, arginase expression and activity 
The effect of diabetes on the activity of ROCK and arginase as well as expression of arginase 
isoforms was determined in the non-ischemic myocardium from diabetic and non-diabetic 
control groups. Both ROCK and arginase activity were significantly elevated in rats with 
diabetes in comparison to non-diabetic animals (Figure 3A and B). There was no difference 
in arginase 1 expression between the two groups (Figure 3C), whereas myocardial expression 
of arginase 2 was significantly increased in diabetic rats (Figure 3D). 
Effect of ROCK inhibition on arginase activity following ischemia-reperfusion
ROCK inhibition significantly attenuated myocardial arginase activity in diabetic rats 
following IR. The effect of ROCK inhibition on arginase activity was reversed by NOS 
inhibition (Figure 4).
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Table 1. Hemodynamic data, part 1. 
  
Group Parameter Baseline Before
reperfusion
60 min
reperfusion
120 min
reperfusion
ND
vehicle
MAP 90±3 81±2 83±5 74±3
HR 426±7 395±12 386±7 367±5
ND
hydroxyfasudil
MAP 85±4 78±3 67±3 72±4
HR 424±9 401±9 373±14 362±5
DM
vehicle
MAP 94±5 80±5 75±2 72±2
HR 340±11 336±8** 324±9** 321±4
DM
hydroxyfasudil
MAP 88±6 84±4 76±3 72±3
HR 342±13*** 325±8*** 325±11** 325±5
DM
L-NMMA+
hydroxyfasudil 
MAP 90±8 88±7 75±5 73±3
HR 335±8*** 336±16** 317±12*** 320±13
DM
L-NMMA
MAP 89±3 77±5 71±4 70±4
HR 344±7*** 349±20 335±5* 331±4
Data are shown as mean±SEM. DM: diabetes mellitus rats; ND: non-diabetic rats; MAP: Mean arterial 
pressure, mmHg; HR: Heart rate, bpm. Significant differences from the ND vehicle group are indicated. 
Data are mean±SEM. * P<0.05; ** P<0.01; *** P<0.001.
Table 2. Hemodynamic data, part 2. 
  
Group Parameter Baseline Beforereperfusion
60 min
reperfusion
120 min
reperfusion
ND
vehicle
MAP 97±10 79±5 76±6 84±6
HR 375±13 416±16 388±12 370±11
ND
nor-NOHA
MAP 98±6 92±5 76±3 81±5
HR 397±15 429±13 371±4 368±6
DM
vehicle
MAP 91±5 82±4 72±3 71±3
HR 345±10 360±12*** 334±8** 330±6*
DM
nor-NOHA
MAP 90±5 80±4 73±3 72±3
HR 322±12** 340±6*** 326±6*** 321±7**
DM
L-NMMA+
nor- NOHA
MAP 90±4 81±6 73±4 71±4
HR 354±15 353±16** 343±10* 342±7
Data are shown as mean±SEM. DM: diabetes mellitus rats; ND: non-diabetic rats; MAP: Mean arterial 
pressure, mm Hg; HR: Heart rate, bpm. Significant differences from the ND vehicle group are indicated. 
Data are mean±SEM. * P<0.05; ** P<0.01; *** P<0.001.
     Rho kinase, arginase and cardioprotection in diabetes
7
Figure 1. (A) Area at risk and (B) infarct size after 30 min of ischemia and 2 h of reperfusion. 
The diabetic (DM) and non-diabetic (ND) rats were given either saline (control, n=5, 
DM; n=5, ND); ROCK inhibitor hydroxyfasudil (HF; n=5, DM; n=5, ND); NO synthase 
inhibitor L-NMMA and hydroxyfasudil (n=5, DM); L-NMMA alone (n=4, DM). 
Data are presented as mean±SEM; ** P<0.01; *** P<0.001. 
Figure 2. (A) Area at risk and (B) infarct size after 30 min of ischemia and 2 h of reperfusion. 
The diabetic (DM) and non-diabetic (ND) rats were given either saline (control, n=14, DM; n=7, ND); 
arginase inhibitor nor-NOHA (n=11, DM; n=8, ND); NO synthase inhibitor L-NMMA and nor-NOHA 
(n=7, DM). Data are presented as mean±SEM; * P<0.05; *** P<0.001. 
Tratsiakovich et al
8
Figure 3. The effect of diabetes on activity of ROCK and arginase and the expression of arginase 
isoforms. (A) Expression of phosphorylated ezrin (p-ezrin) as a marker of ROCK activity, (B) 
arginase activity, (C) expression of arginase 1 and (D) arginase 2 in non-ischemic myocardium from 
non-diabetic (ND) and diabetic rats (DM) including representative immunoblots. Data are shown as 
mean±SEM; n=5-10; *P<0.05; **P<0.01.
Figure 4. The effect of ROCK inhibition on arginase activity following ischemia-reperfusion. 
Myocardial arginase activity in rats with diabetes mellitus subjected to control ischemia-reperfusion 
(DM control), ROCK inhibition by hydroxyfasudil (DM HF), the combination of NOS inhibition 
and ROCK inhibition (DM L-NMMA+HF), and NOS inhibition alone (DM L-NMMA). Data are 
presented as mean±SEM; n=4-5; **P<0.01; ***P<0.001.
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Discussion and conclusions
In this study we show that ROCK activity, arginase activity and arginase 2 protein 
expression are upregulated in the myocardium of type 1 diabetic rats. Inhibition of ROCK by 
hydroxyfasudil protects the diabetic heart from IR injury. The cardioprotective effect of ROCK 
inhibition is associated with significant decrease of arginase activity in ischemic-reperfused 
myocardium. In turn, inhibition of arginase by nor-NOHA protects the diabetic heart from IR 
injury emphasizing the importance of arginase for the deleterious consequences of IR injury 
in diabetes. The protective effects of both ROCK and arginase inhibition are abolished by 
the NOS-inhibitor L-NMMA. These observations indicate that ROCK inhibition provides 
protection against IR injury via a mechanism that involves downregulation of arginase and 
increased bioavailability of NO. Furthermore, both ROCK inhibition and arginase inhibition 
provide effective protection from IR injury in the setting of diabetes.
  
It is well established that attenuation of NO bioavailability is a dominant mechanism 
contributing to IR injury27 and cardiovascular complications associated with diabetes28. 
Although the underlying mechanisms are not fully understood, recent data suggest that 
upregulation of ROCK5 and arginase6 are involved in signaling events leading to reduction 
in NO bioavailability. We therefore hypothesized that these signaling pathways are of 
importance for the development of IR injury in diabetes and targeting them would result in 
reduction in infarct size in a model of diabetes. Furthermore, there seems to be an intriguing 
link between ROCK and arginase whereby activation of arginase involves activation of 
ROCK.13, 29 Whether this is of functional importance in the setting of IR has previously not 
been investigated.
Based on the involvement of ROCK in the signaling events contributing to IR injury7 and 
its key function in the development of diabetic vascular complications, we first investigated 
whether targeting ROCK had beneficial effects in the setting of myocardial IR in diabetes. 
Accordingly, we found that myocardial ROCK activity was upregulated in rats with diabetes. 
Of further importance, administration of the ROCK inhibitor hydroxyfasudil attenuated 
infarct size in rats with type 1 diabetes. This cardioprotective effect of ROCK inhibition 
was abolished by NOS inhibition supporting the notion that cardioprotection from ROCK 
inhibition is mediated via a NOS-dependent mechanism in diabetes.
 
Given the previous data suggesting that ROCK may stimulate arginase activity and that 
arginase may be involved in the development of IR injury, we next investigated the effect of 
ROCK inhibition on arginase activity and the efficacy of arginase inhibition to reduce IR. 
Recent studies have been shown that diabetes is associated with elevation of arginase activity 
and impairment of vascular endothelial function characterized by low availability of NO.17, 21 
Furthermore, ROCK is reported as a trigger for increased arginase activity in diabetes.24 It was 
found that the ROCK inhibitor hydroxyfasudil markedly attenuated the increase in arginase 
activity induced by IR demonstrating that arginase activity induced by IR is mediated via 
a signaling pathway involving ROCK. This observation in rats with type 1 diabetes is in 
line with that obtained in non-diabetic rats15 and supports the notion that arginase activity 
is influenced by ROCK activity. Administration of the NOS inhibitor L-NMMA reversed 
the downregulation of arginase activity induced by the ROCK inhibitor hydroxyfasudil in 
diabetes but did not modify arginase activity per se in the presence of diabetes. This effect 
suggests that inhibition of NOS by L-NMMA shifted the utilization of L-arginine to arginase. 
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It was in addition demonstrated that inhibition of arginase reduced infarct size in rats with 
type 1 diabetes via an effect that was dependent on NOS activity. The cardioprotective effects 
induced by ROCK inhibition and arginase inhibition together with the observation that the 
ROCK inhibitor hydroxyfasudil decreased arginase activity collectively suggest that ROCK 
reduces infarct size via a mechanism including downregulation of arginase and increased 
bioavailability of NO.
Cardioprotective treatment strategies aimed at limiting IR injury have been described to be 
attenuated or absent in animal models of diabetes. Thus, it has been shown that the diabetic 
heart is more resistant to pharmacological and non-pharmacological (classical pre- and 
postconditioning) treatments aiming at reducing IR injury.25 In addition, we have recently 
shown that remote ischemic perconditioning which markedly reduced infarct size in non-
diabetic rats failed to induce cardioprotective effect in type 1 diabetic rats.15 It is therefore 
an unmet need to develop treatment strategies that protect the myocardium in the presence 
of diabetes. The present study provides evidence that pharmacological inhibition of ROCK 
and arginase effectively reduce infarct size by magnitudes comparable to that obtained in 
non-diabetic animals. This opens up for new possibilities for treatment of diabetic disorders. 
Certain limitations of the study need to be acknowledged. These data are obtained in a model 
of type 1 diabetes and it is not known whether similar results are valid for other models of 
diabetes. There was no significant difference in the vulnerability to IR in type 1 diabetic 
hearts in comparison with non-diabetic hearts. This is in agreement with previous studies, 
although some studies have described both smaller and larger infarct size in various animal 
models of diabetes.25 Of importance, the purpose of the present study was to investigate the 
efficacy of the cardioprotective interventions, not to compare the extent of IR injury per 
se between diabetes and non-diabetes. The presently used model is known to be resistant 
to cardioprotection induced by remote ischemic perconditioning, demonstrating a marked 
difference from non-diabetic rats and thereby the suitability of the model for this type of 
study.15
In conclusion, the present study demonstrates that myocardial ROCK activity, arginase 
activity and arginase 2 expression are increased in type 1 diabetic animals. Both ROCK 
and arginase inhibition reduce infarct size via a NOS–dependent mechanism. Furthermore, 
the cardioprotective effect of ROCK-inhibition involves downregulation of arginase. These 
findings suggest that ROCK and arginase are promising therapeutic targets for limitation of 
myocardial injury in diabetes. 
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